



## CONTENTS

---

Frontispiece—Ian M. Glynn	xiv
<b>PERSPECTIVES, Joseph F. Hoffman, Editor</b>	
A Hundred Years of Sodium Pumping, Ian M. Glynn	1
<b>CELL PHYSIOLOGY, Paul De Weer, Section Editor</b>	
Potassium Channel Ontogeny, Carol Deutsch	19
<b>ENDOCRINOLOGY, Bert W. O'Malley, Section Editor</b>	
Prolactin: The New Biology of an Old Hormone, Vincent Goffin, Nadine Binart, Philippe Touraine, and Paul A. Kelly	47
Ovulation: New Dimensions and New Regulators of the Inflammatory-Like Response, JoAnne S. Richards, Darryl L. Russell, Scott Ochsner, and Lawrence L. Espey	69
Aromatase—A Brief Overview, Evan R. Simpson, Colin Clyne, Gary Rubin, Wah Chin Boon, Kirsten Robertson, Kara Britt, Caroline Speed, and Margaret Jones	93
<b>SPECIAL TOPIC: G PROTEIN EFFECTOR MECHANISMS, James Hurley, Special Topic Editor</b>	
G Proteins and Pheromone Signaling, Henrik G. Dohlman	129
G Proteins and Phototransduction, Vadim Y. Arshavsky, Trevor D. Lamb, and Edward N. Pugh, Jr.	153
G Proteins and Olfactory Signal Transduction, Gabriele V. Ronnett and Cheil Moon	189
<b>COMPARATIVE PHYSIOLOGY, George N. Somero, Section Editor</b>	
Mycosporine-Like Amino Acids and Related Gadusols: Biosynthesis, Accumulation, and UV-Protected Functions in Aquatic Organisms, J. Malcolm Shick and Walter C. Dunlap	223
Hypoxia-Induced Anapnoea: Implications and Putative Mediators, Alexandre A. Steiner and Luiz G. S. Branco	263

**NEUROPHYSIOLOGY, Richard W. Tsien, Section Editor**

- Calmodulin as an Ion Channel Subunit, *Yoshiro Saimi and Ching Kung* 289
- Structure and Function of Dendritic Spines, *Esther A. Nimchinsky, Bernardo L. Sabatini, and Karel Svoboda* 313
- Short-Term Synaptic Plasticity, *Robert S. Zucker and Wade G. Regehr* 355

**CARDIOVASCULAR PHYSIOLOGY, Jeffrey Robbins, Section Editor**

- Intracellular Transport Mechanisms of Signal Transducers, *Gerald W. Dorn, II and Daria Mochly-Rosen* 407
- Cardiac Ion Channels, *Dan M. Roden, Jeffrey R. Balser, Alfred L. George, Jr., and Mark E. Anderson* 431
- Fatty Acid Oxidation Disorders, *Piero Rinaldo, Dietrich Matern, and Michael J. Bennett* 477

**RENAL AND ELECTROLYTE PHYSIOLOGY, Steven C. Hebert, Section Editor**

- Molecular Chaperones in the Kidney, *Steven C. Borkan and Steven R. Gullans* 503
- Molecular Mechanism of Active  $\text{Ca}^{2+}$  Reabsorption in the Distal Nephron, *Joost G. J. Hoenderop, Bernd Nilius, and René J. M. Bindels* 529
- The Renin Angiotensin System and Kidney Development, *Taiji Matsusaka, Yoichi Miyazaki, and Iekuni Ichikawa* 551
- Molecular Aspects of Renal Anionic Drug Transporters, *Frans G. M. Russel, Rosalinde Masereeuw, and Rémon A. M. H. van Aubel* 563

**GASTROINTESTINAL PHYSIOLOGY, Luis Reuss, Section Editor**

- Trafficking of Canalicular ABC Transporters in Hepatocytes, *Helmut Kipp and Irwin M. Arias* 595
- Chloride Channels and Hepatocellular Function: Prospects for Molecular Identification, *Xinhua Li and Steven A. Weinman* 609
- Bile Salt Transporters, *Peter J. Meier and B. Stieger* 635
- Mechanisms of Iron Accumulation in Hereditary Hemochromatosis, *Robert E. Fleming and William S. Sly* 663


**RESPIRATORY PHYSIOLOGY, Carole R. Mendelson, Section Editor**

- Molecular Pathogenesis of Lung Cancer, *Sabine Zöchbauer-Müller, Adi F. Gazdar, and John D. Minna* 681

$\beta$ -Defensins in Lung Host Defense, <i>Brian C. Schutte and Paul B. McCray, Jr.</i>	709
Regulation of Endothelial Nitric Oxide Synthase: Location, Location, Location, <i>Philip W. Shaul</i>	749
GM-CSF Regulates Pulmonary Surfactant Homeostasis and Alveolar Macrophage-Mediated Innate Host Defense, <i>Bruce C. Trapnell and Jeffrey A. Whitsett</i>	775
<b>SPECIAL TOPIC: TRANSPORTOPATHIES, Gerhard Giebisch, Special Topic Editor</b>	
Human and Murine Phenotypes Associated with Defects in Cation-Chloride Cotransport, <i>Eric Delpire and David B. Mount</i>	803
Renal Genetic Disorders Related to $K^+$ and $Mg^{2+}$ , <i>David G. Warnock</i>	845
Epithelial Sodium Channel and the Control of Sodium Balance: Interaction Between Genetic and Environmental Factors, <i>Bernard C. Rossier, Sylvain Pradervand, Laurent Schild, and Edith Hummler</i>	877
Genetic Diseases of Acid-Base Transporters, <i>Seth L. Alper</i>	899
<b>INDEXES</b>	
Subject Index	925
Cumulative Index of Contributing Authors, Volumes 60–64	957
Cumulative Index of Chapter Titles, Volumes 60–64	960

**ERRATA**

An online log of corrections to *Annual Review of Physiology* chapter may be found at <http://physiol.annualreviews.org/errata.shtml>



# SUBJECT INDEX

- A**
- ABCC genes**
  - renal organic anionic transporters and, 574-75
- ABC transporters**
  - cardiac ion channels and, 457
- Ablation**
  - GM-CSF regulation of lung functions and, 786-89, 793
- Absorption**
  - iron accumulation in hereditary hemochromatosis and, 663-74
- Acetylcholine**
  - cardiac ion channels and, 457-58
  - endothelial nitric oxide synthase regulation and, 753, 759, 763-65
- Acid-base transporters**
  - genetic diseases of
    - acid-base disturbances secondary to genetic disorders of renal  $\text{Na}^+$  reabsorption, 915-16
  - AE1 mutations, 902-6
  - carbonic anhydrase II mutations, 914-15
  - $\text{Cl}^-$  channel diseases, 911-16
  - conclusions, 916
  - familial distal renal tubular acidosis, 901-10
  - introduction, 899-900
  - mixed renal tubular acidosis, 914-15
  - NBC1* mutations, 913-14
  - osteopetrosis, 910-11
  - proximal renal tubular acidosis, 913-14
  - SLC26A  $\text{Cl}^-$ /base exchangers, 906-11
  - urinary acidification, 900-6
  - $\text{vH}^+$ -ATPase subunit mutations, 907-11
- Action potentials**
  - cardiac ion channels and, 431, 433-35
- Activation**
  - active  $\text{Ca}^{2+}$  absorption in distal nephron and, 529
  - G proteins and phototransduction, 156
  - hepatocyte chloride channels and, 609-16
  - intracellular signal transport and, 22-38
  - prolactin receptor and, 49-50
  - short-term synaptic plasticity and, 375-76
- Acylcarnitine**
  - fatty acid  $\beta$ -oxidation disorders and, 485
- ADAMTS-1 gene**
  - ovulation regulators and, 69, 74, 76, 78-83
- Adaptive immunity**
  - $\beta$ -defensins in lung host defense and, 709, 733-34
- Adenomatous polyposis coli**
  - lung cancer molecular pathogenesis and, 690-91
- Adenosine**
  - hypoxia-induced anapnoea and, 263, 270
- Adenosine diphosphate (ADP)**
  - sodium pumping and, 1, 9-10, 12-13
- Adenosine triphosphate (ATP)**
  - cardiac ion channels and, 433, 446, 458
  - G proteins and phototransduction, 166
  - hepatocyte chloride channels and, 611-14, 618
  - intracellular signal transport and, 411
  - renal molecular chaperones and, 507-12
  - sodium pumping and, 1, 5-13
- Adenylyl cyclases**
  - G proteins and olfactory signal transduction, 189, 198-99
- Adipose tissue**
  - aromatase and, 100-4, 114-15
- Adrenocortical tumor**
  - aromatase and, 108
- Adrenocorticotrophic hormone (ACTH)**
  - renal genetic disorders related to  $\text{K}^+$  and  $\text{Mg}^{2+}$ , 845-66
- AE1 anion exchanger**
  - genetic diseases of acid-base transporters and, 899, 902-6
- Agarica agaracites**
  - MAAs in aquatic organisms and, 239

- Agenesis of corpus callosum  
   and peripheral  
   neuropathy (ACCPN)  
   cation-Cl cotransporter  
   phenotypes and, 828–29
- Aggrecan  
   ovulation regulators and,  
   79, 82
- Aging  
   dendritic spines and,  
   329–30
- Air-liquid interface  
   ENaC and sodium balance,  
   877, 882–83
- Airway epithelium  
   endothelial nitric oxide  
   synthase regulation and,  
   749–51
- AIS oncogene  
   lung cancer molecular  
   pathogenesis and, 686
- A kinase anchoring proteins  
   (AKAPs)  
   cardiac ion channels and,  
   442, 446, 454  
   intracellular signal  
   transport and, 420–21
- AKR1 protein  
   G proteins and pheromone  
   signaling, 137–40
- AKT1 channel  
   K<sup>+</sup> channel ontogeny and,  
   25
- Aldosterone  
   cation-Cl cotransporter  
   phenotypes and, 815,  
   817–18  
   ENaC and sodium balance,  
   877, 880–82, 884–87,  
   889–90  
   renal genetic disorders  
   related to K<sup>+</sup> and Mg<sup>2+</sup>,  
   848–51, 857–59, 862
- Alexandrium excavatum*  
   MAAs in aquatic  
   organisms and, 245, 248
- Algae
- MAAs in aquatic  
   organisms and, 223,  
   227–29, 231, 245–49
- Allele loss  
   lung cancer molecular  
   pathogenesis and, 681,  
   686–93
- Allelic polymorphisms  
   ENaC and sodium balance,  
   889
- Alveolar macrophages  
   GM-CSF regulation of lung  
   functions and, 775–95
- Amiloride  
   cation-Cl cotransporter  
   phenotypes and, 817–18  
   ENaC and sodium balance,  
   880–83, 887  
   renal genetic disorders  
   related to K<sup>+</sup> and Mg<sup>2+</sup>,  
   857
- Amino acids  
   MAAs in aquatic  
   organisms and, 223–52
- 4-Aminopyridine  
   cardiac ion channels and,  
   456
- AMPA receptor  
   dendritic spines and, 318,  
   323–24  
   short-term synaptic  
   plasticity and, 386
- Amphioxus* spp.  
   aromatase and, 96
- Amplification  
   G proteins and  
   phototransduction, 153,  
   157–60, 165–67
- Anapnyrexia  
   hypoxia-induced, 263–79
- Anchoring proteins  
   intracellular signal  
   transport and, 407,  
   409–21, 423
- Andersen's syndrome  
   cardiac ion channels and,  
   457
- Androgens  
   aromatase and, 93–119
- Androstenedione  
   aromatase and, 117
- Angiogenesis  
   lung cancer molecular  
   pathogenesis and, 681,  
   691–93
- Angiotensin  
   cation-Cl cotransporter  
   phenotypes and, 815  
   ENaC and sodium balance,  
   889  
   kidney development and,  
   45–52
- Anthopleurins  
   cardiac ion channels and,  
   442  
   MAAs in aquatic  
   organisms and, 234
- Antioxidant defenses  
   MAAs in aquatic  
   organisms and, 223,  
   233–35
- APC gene/*wnt* pathway  
   lung cancer molecular  
   pathogenesis and, 690–91
- Apical membrane  
   bile-salt transporters and,  
   639, 648–49  
   genetic diseases of  
   acid-base transporters  
   and, 899–916
- Apical transport  
   renal organic anionic  
   transporters and, 565,  
   572, 582
- Aplysia* spp.  
   intracellular signal  
   transport and, 412  
   short-term synaptic  
   plasticity and, 381, 383,  
   386
- Apoptosis  
   hepatocyte chloride  
   channels and, 609,  
   616–18

- lung cancer molecular pathogenesis and, 685, 688
- renal molecular chaperones and, 503, 509, 511–16, 518
- Apparent mineralocorticoid excess (AME) syndrome
- cation-Cl cotransporter phenotypes and, 818
- renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 851–52
- Arabidopsis* spp.
- MAAs in aquatic organisms and, 252
- Arginine vasopressin (AVP)
- hypoxia-induced anapnyxia and, 268–69, 273
- Aromatase
- adipose phenotype, 114–15
- adipose tissue, 100–4
- ArKO mouse
- female, 113–14
- male, 111–13
- bone, 106
- brain, 106–7
- conclusions, 115–19
- genetics, 94–98
- human deficiency, 109–10
- insufficiency models, 109–15
- introduction, 93–94
- local estrogen biosynthesis, 115–19
- malignant cells, 108
- miscellaneous tissues, 107–8
- ovary, 99–100
- ovulation regulators and, 70
- placenta, 105–6
- skeleton, 115
- structure/function relationships, 98–99
- tissue-specific expression, 99–108
- Arrhythmias
- cardiac ion channels and, 431–61
- Arterial blood flow
- obstruction
- renin angiotensin system and kidney development, 45–52
- Arthritis
- iron accumulation in hereditary hemochromatosis and, 663
- Asbt* bile salt transporter
- bile-salt transporters and, 635, 639, 647–48
- Ascidia ceratodes*
- MAAs in aquatic organisms and, 249
- ASG7 protein
- G proteins and pheromone signaling, 137–40
- ASL peptide
- $\beta$ -defensins in lung host defense and, 735–37
- Aspergillus* spp.
- calmodulin as ion-channel subunit and, 291
- G proteins and pheromone signaling, 141
- Asterina pectinifera*
- MAAs in aquatic organisms and, 226
- AT1 receptor
- renin angiotensin system and kidney development, 45–52
- Atherosclerosis
- endothelial nitric oxide synthase regulation and, 749
- ATPases
- active  $Ca^{2+}$  absorption in distal nephron and, 529–30
- genetic diseases of acid-base transporters and, 899, 907–11
- sodium pumping and, 1, 6–13
- ATP-binding cassette (ABC) transporters
- bile-salt transporters and, 635, 639, 644, 646–47, 650
- cardiac ion channels and, 457
- trafficking of trafficking of canalicular ABC transporters in hepatocytes and characteristics of intrahepatic ABC transporter pools, 600–3
- conclusions, 605
- intrahepatic regulation, 603–5
- introduction, 595–96
- newly synthesized ABC transporters, 596–99
- renal organic anionic transporters and, 574–75
- ATXII
- cardiac ion channels and, 442
- Augmentation
- short-term synaptic plasticity and, 355, 360–61, 366
- Autocrine factors
- lung cancer molecular pathogenesis and, 682–84
- Autoimmunity
- GM-CSF regulation of lung functions and, 787
- Avogadro's number
- G proteins and phototransduction, 159

- B**
- Background current  
cardiac ion channels and, 460
- Bacteria  
aromatase and, 98  
 $\beta$ -defensins in lung host defense and, 709–37
- “Ball and chain” model  
cardiac ion channels and, 440, 456
- Bartter’s syndrome  
cation-Cl cotransporter phenotypes and, 803, 811, 814–16, 820  
ENaC and sodium balance, 880  
renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845, 853–54, 864–65
- Basolateral transport  
bile-salt transporters and, 638–44, 650  
genetic diseases of acid-base transporters and, 899–916  
renal organic anionic transporters and, 565, 581
- Bathymetric distribution  
MAAs in aquatic organisms and, 230–31
- BayK8644  
cardiac ion channels and, 446
- BCL-2* proto-oncogene  
lung cancer molecular pathogenesis and, 685
- Benzothiazepines  
cardiac ion channels and, 445
- Bikunin  
ovulation regulators and, 73
- Bile acid receptor  
bile-salt transporters and, 638, 641–42, 646, 649–50
- Bile-salt transporters  
apical bile-salt uptake, 648–49  
basolateral bile-salt efflux, 644, 650  
basolateral bile-salt uptake, 638, 640–44  
bile duct epithelial cells, 647–50  
canalicular secretion, 646–47  
conclusions, 650–51  
cytosolic bile-salt-binding proteins, 650  
enterohepatic circulation, 635–40  
hepatocytes, 638–40  
intracellular transport, 644–45  
 $Na^+$ -taurocholate cotransporting proteins, 638, 640–42  
organic anion-transporting polypeptides, 642–44  
perspectives, 650–51  
small intestine, 648
- Bile secretion  
trafficking of canalicular ABC transporters in hepatocytes and, 595–605
- Biogenesis  
 $K^+$  channel ontogeny and, 19–31, 35–37
- Birth  
renin angiotensin system and kidney development, 555–57
- BK channels  
 $K^+$  channel ontogeny and, 28
- BLAST searches  
aromatase and, 95
- Blood volume  
ENaC and sodium balance, 877–78
- Body temperature  
hypoxia-induced anapnoea and, 263–79
- Bone  
aromatase and, 93, 106, 115  
prolactin and, 57
- Bradykinin  
endothelial nitric oxide synthase regulation and, 762–65
- Brain  
aromatase and, 93, 96, 106–7, 115  
cation-Cl cotransporter phenotypes and, 803–43  
dendritic spines and, 323–42
- Breast cancer  
aromatase and, 93, 103–4, 108, 118  
prolactin and, 47, 52, 55–56, 59
- Brevican  
ovulation regulators and, 79
- Brugada syndrome  
cardiac ion channels and, 443–44, 461
- Bsep export pump  
bile-salt transporters and, 635, 639–40, 646–47
- Bufo* spp.  
hypoxia-induced anapnoea and, 267, 269
- Bumetanide  
cation-Cl cotransporter phenotypes and, 814
- C**
- C*<sub>19</sub> steroid precursors  
aromatase and, 93, 99
- C282Y* mutant  
iron accumulation in hereditary hemochromatosis and, 667–68
- $Ca^{2+}$   
calmodulin as ion-channel subunit and, 289–305



- cardiac ion channels and, 435, 437–38, 440, 444–47
- dendritic spines and, 313–14, 316, 319, 325–29, 333–41
- endothelial nitric oxide synthase regulation and, 749–68
- G proteins and olfactory signal transduction, 200–4, 207–8
- G proteins and phototransduction, 155, 170–71
- hepatocyte chloride channels and, 609, 615–16
- intracellular signal transport and, 420–21
- K<sup>+</sup> channel ontogeny and, 28, 37
- molecular mechanism of active absorption in distal nephron and calbindin-D<sub>28K</sub>, 537–39
- clinical implications, 543–44
- epithelial Ca<sup>2+</sup> channel, 530–37, 540–42
- extrusion mechanisms, 539
- family of EcaC channels, 537
- future research, 543–44
- hypocalciurea, 540–41
- integrated model of active Ca<sup>2+</sup> reabsorption, 542–44
- introduction, 529–30
- localization, 532
- 1,25(OH)<sub>2</sub>D<sub>3</sub>, 539–40
- pH sensitivity, 541
- potential regulators, 542
- regulation, 531–32, 540–42
- thiazide diuretics, 540–41
- transport proteins, 530–31
- renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 848–50, 854–57, 863–66
- short-term synaptic plasticity and, 355, 359–68
- Ca<sup>2+</sup>-ATPase
- active Ca<sup>2+</sup> absorption in distal nephron and, 529–30
- Ca<sup>2+</sup>-binding proteins
- short-term synaptic plasticity and, 381–85
- Caenorhabditis elegans*
- calmodulin as ion-channel subunit and, 291
- cardiac ion channels and, 460
- genetic diseases of acid-base transporters and, 910
- ovulation regulators and, 81, 83
- Calbindin-D<sub>28K</sub>
- active Ca<sup>2+</sup> absorption in distal nephron and, 529–30, 537–39
- Calmodulin
- as ion-channel subunit
- Ca<sup>2+</sup>-activated K<sup>+</sup> channels of small or intermediate conductance, 296–97
- Ca<sup>2+</sup> channels, 298–300
- Ca<sup>2+</sup> chemistry of ion channels, 292–301
- Ca<sup>2+</sup> sensor and mechanical coupling, 301–2
- functional bipartition, 302–4
- conclusions, 304–5
- cyclic nucleotide-gate channels, 293–94
- functional bipartition, 302–4
- inositol-1,4,5-triphosphate receptor, 295–96
- introduction, 289
- miscellaneous channels, 300–1
- NMDA receptors, 294–95
- opposing effects, 302–4
- overview, 290–92
- ryanodine receptor, 295–96
- Trp family channels, 297–98
- K<sup>+</sup> channel ontogeny and, 37
- Calnexin
- K<sup>+</sup> channel ontogeny and, 23
- Canalicular domain
- trafficking of ABC transporters in hepatocytes and, 595–605
- Canalicular membrane
- bile-salt transporters and, 635, 639, 646–47
- Cancer
- aromatase and, 93, 103–4, 108, 118
- iron accumulation in hereditary hemochromatosis and, 663
- lung cancer molecular pathogenesis and, 681–98
- prolactin and, 47, 52
- Candida pseudotropicalis*
- GM-CSF regulation of lung functions and, 789–90
- Carbenoxolone
- renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 858
- Carbon monoxide
- hypoxia-induced anapnoea and, 271, 274–76

- Carbonic anhydrase II  
genetic diseases of  
acid-base transporters  
and, 899, 914–15
- Cardiac channel activation  
intracellular signal  
transport and, 414–15
- Cardiac ion channels  
acquired disease, 443–44  
action potentials, 433–35  
background current, 460  
Ca<sup>2+</sup> channel, 446–47  
Ca<sup>2+</sup> current, 444–47  
cloning, 435–38  
congenital disease, 442–43  
delayed rectifier K<sup>+</sup>  
currents, 448–57  
drug and toxin block, 440  
future research, 460–61  
genes, 432, 435–38  
I<sub>Ca</sub>, 445–46  
I<sub>Na</sub>, 442  
inactivation, 440  
introduction, 431–32  
inward rectifiers, 457–58  
Ito transient outward  
current, 447–48  
*KvLQT1-minK* channel,  
454–55  
molecular structure/  
function relationships,  
438–42, 445, 449–50,  
453, 456–58  
Na<sup>+</sup> current, 440–44  
pacemaker current, 458–59  
permeation, 438  
rapid component of I<sub>Kr</sub>  
delayed rectifier current,  
448  
rapid component of I<sub>Kr</sub>  
ultrarapid delayed  
rectifier current, 456–57  
rapid component of I<sub>Ks</sub>  
slow delayed rectifier  
current, 453–55  
regulation, 442–48,  
451–52, 454, 456–57  
structure/function  
relationships, 449–51,  
453, 456–58  
voltage gating, 438–39
- Carnitine  
fatty acid  $\beta$ -oxidation  
disorders and, 477,  
479–81, 483–85, 489–90,  
492–95
- Carnitine: acylcarnitine  
translocase deficiency  
fatty acid  $\beta$ -oxidation  
disorders and, 485
- Carnitine  
palmitoyltransferase I/II  
deficiency  
fatty acid  $\beta$ -oxidation  
disorders and, 484–85
- Catabolism  
GM-CSF regulation of  
lung functions and, 775,  
782, 786
- Cathepsin L* gene  
ovulation regulators and,  
76, 78–82
- Cation-Cl cotransport  
human and murine  
phenotypes  
absorptive KCC2  
cotransporter, 823–26  
absorptive KCC3  
cotransporter, 826–29  
absorptive KCC1  
cotransporter, 822–23  
absorptive Na-Cl  
cotransporter, 818–22  
absorptive Na-K-2Cl  
cotransporter, 813–18  
agenesis of corpus  
callosum and  
peripheral neuropathy,  
828–29  
Bartter syndrome,  
814–16  
blood pressure, renin  
phenotype, 810  
conclusions, 829  
epilepsy, 824–25  
gain-of-function  
mutations, 821–22  
gene disruption, 808,  
816–18, 820–21, 824,  
827–28  
Gitelman syndrome, 820  
hemoglobinopathies,  
822–23  
human disease, 811–12,  
821–22  
intestinal henotype, 809  
introduction, 804–5  
kidney, 827  
male infertility, 810  
Na<sup>+</sup>-dependent  
cotransporters, 806–21  
Na<sup>+</sup>-independent K-Cl  
cotransporters, 822–29  
nervous system, 827  
neurons, 825, 826  
NKCC1 cotransporter,  
806–12  
NKCC2 cotransporter,  
813–18  
salivary gland  
phenotype, 809  
secretory Na-K-2Cl  
cotransporter, 806–12  
sensorineural deafness,  
808  
sensory perception  
phenotype, 810–11
- Caveolae  
endothelial nitric oxide  
synthase regulation and,  
749, 753–68
- CCR6 receptor  
 $\beta$ -defensins in lung host  
defense and, 709
- CD9 protein  
ovulation regulators and,  
81
- CDC24 protein  
G proteins and pheromone  
signaling, 132–35
- C/EBP proteins

- aromatase and, 103, 105  
ovulation regulators and, 77-78
- Cell surface receptors  
G proteins and pheromone signaling, 129-43  
 $K^+$  channel ontogeny and, 19-37
- Central nervous system (CNS)  
G proteins and olfactory signal transduction, 189-210  
hypoxia-induced anapryxia and, 263-79
- cGMP phosphodiesterase  
G proteins and phototransduction, 153, 168-69, 172-73
- Chaperones  
 $K^+$  channel ontogeny and, 23-24, 32  
renal molecular  
ATP depletion, 507-12  
chronic, progressive renal failure, 515-16  
future research, 518  
glomerulonephritis, 514-15  
historical perspective, 504  
immune-mediated injury, 514-15  
induction of cellular stress response, 506-7  
introduction, 503-4  
ischemia, 507-12  
nephrotoxin exposure, 512-14  
normal renal function, 504-7  
obstructive nephropathy, 514  
osmotic stress, 516-18  
renal transplantation, 516
- Chemokines  
 $\beta$ -defensins in lung host defense and, 709
- Chloride (ClC) channels  
hepatocellular function and  $Ca^{2+}$ -activated chloride channels, 615-16  
cAMP-activated chloride channels, 616  
cell injury, 616-18  
ClC chloride channel family, 620-25  
CLIC chloride channel family, 621  
conclusions, 625-26  
endoplasmic reticulum, 619  
functional identification, 618-20  
intracellular chloride channels, 618-25  
introduction, 609-10  
lysosomes, 618-19  
Mid-1 related chloride channel, 625  
mitochondrial voltage-dependent anion channel, 625  
molecular identification, 620-25  
nuclear membrane, 619-20  
plasma membrane chloride channels, 610-16  
properties, 621  
swelling-activated chloride channels, 610-15
- Chlorogloeopsis* spp.  
MAAs in aquatic organisms and, 242
- Chlorothiazide  
renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 855
- Cholehepatic shunting  
bile-salt transporters and, 635-37, 651
- Cholestasis  
trafficking of canalicular ABC transporters in hepatocytes and, 595-605
- Cholesterol  
aromatase and, 114  
bile-salt transporters and, 635-36, 638, 651  
endothelial nitric oxide synthase regulation and, 757-61, 764
- Chondrus* spp.  
MAAs in aquatic organisms and, 226, 238, 248-49
- Chronic, progressive renal failure  
renal molecular chaperones and, 515-16
- $\alpha$ -Chymotrypsin  
sodium pumping and, 13
- $Cl^-$   
genetic diseases of acid-base transporters and, 899-916  
G proteins and olfactory signal transduction, 200-4, 207-8
- CLC channels  
genetic diseases of acid-base transporters and, 899-916  
hepatocyte chloride channels and, 620-25
- CLIC channels  
hepatocyte chloride channels and, 609, 621
- Cloning  
cardiac ion channels and, 435-38  
renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845  
renal organic anionic transporters and, 563, 572-78  
trafficking of canalicular

- ABC transporters in hepatocytes and, 595
- Clustering  
K<sup>+</sup> channel ontogeny and, 33–34
- Collagen  
ovulation regulators and, 76, 79
- Compartmentalization  
endothelial nitric oxide synthase regulation and, 749, 763  
hepatocyte chloride channels and, 609, 618–25
- Compartmental models  
dendritic spines and, 332–34
- Conduction system disease  
cardiac ion channels and, 443
- Cones  
G proteins and phototransduction, 155–56, 175–76
- $\mu$ -Conotoxins  
cardiac ion channels and, 442
- Consumer organisms  
MAAs in aquatic organisms and, 249–51
- Corals  
MAAs in aquatic organisms and, 223, 240–41
- Corpus callosum  
cation-Cl cotransporter phenotypes and, 828–29
- Cortisol  
aromatase and, 104  
ENaC and sodium balance, 881  
renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 845, 850
- Cotranslational regulation  
endothelial nitric oxide synthase regulation and, 749
- Cotransporters  
cation-Cl cotransporter phenotypes and, 803–43
- COUP-TF protein  
aromatase and, 108
- COX-2 gene  
ovulation regulators and, 71–75, 77
- CREB transcription factor  
aromatase and, 96, 99–100
- Cross-talk  
G proteins and olfactory signal transduction, 189–210  
K<sup>+</sup> channel ontogeny and, 19, 36–37
- C-terminal domains  
active Ca<sup>2+</sup> absorption in distal nephron and, 529
- Cumulus  
ovulation regulators and, 69–84
- Cyclic adenosine monophosphate (cAMP)  
aromatase and, 96, 99, 102, 106–7, 117  
bile-salt transporters and, 641–42  
cardiac ion channels and, 460  
G proteins and olfactory signal transduction, 197–98  
hepatocyte chloride channels and, 616  
hypoxia-induced anapnoea and, 276–77  
intracellular signal transport and, 409, 420  
ovulation regulators and, 70, 79  
trafficking of canalicular ABC transporters in hepatocytes and, 595
- Cyclic guanosine monophosphate (cGMP)  
G proteins and olfactory signal transduction, 205–7
- G proteins and phototransduction, 156, 167–69  
hypoxia-induced anapnoea and, 272–73, 275–78
- Cyclical carrier model  
sodium pumping and, 9
- Cyclic nucleotide-gated (CNG) channels  
calmodulin as ion-channel subunit and, 293–94
- Cyclic nucleotides  
G proteins and olfactory signal transduction, 201–4
- Cyclins  
ovulation regulators and, 70, 78
- CYP19 gene  
aromatase and, 94–95, 97–98, 111
- Cytochrome P450  
aromatase and, 94, 97–99
- Cytokines  
aromatase and, 96, 100–2, 104, 106, 117  
 $\beta$ -defensins in lung host defense and, 709  
prolactin and, 48
- Cytosol  
K<sup>+</sup> channel ontogeny and, 19–37
- Cytosolic bile-salt-binding proteins  
bile-salt transporters and, 650
- ## D
- DAMGO  
hypoxia-induced anapnoea and, 271
- DASH diet  
ENaC and sodium balance, 879

- dDAVP  
 · renal genetic disorders  
 related to  $K^+$  and  $Mg^{2+}$ ,  
 862
- Deafferentation-induced  
 plasticity  
 dendritic spines and, 322
- Deafness  
 cation-Cl cotransporter  
 phenotypes and, 808–9  
 genetic diseases of  
 acid-base transporters  
 and, 899, 905–7, 909
- $\beta$ -Defensins  
 lung host defense and  
 adaptive immunity,  
 733–34  
 animal species, 727, 728  
 antimicrobial activity,  
 711–13, 731–32  
 ASL peptide, 735–37  
 clinical applications, 737  
 constitutive expression,  
 729–31  
 epithelial  $\beta$ -defensins,  
 713–14  
 genes and gene products,  
 714–19, 723–28,  
 734–35  
 inducible expression,  
 729–31  
 innate defense, 710–11  
 introduction, 709  
 respiratory epithelium,  
 728–29  
 synergy among  
 components of airway  
 surface liquid, 732–33  
 vertebrate  $\beta$ -defensin  
 structure, 719–23
- Dehydroepiandrosterone  
 (DHEA)  
 aromatase and, 109,  
 116–17
- Delayed rectifier  $K^+$  currents  
 cardiac ion channels and,  
 448–57
- Dendritic cells  
 $\beta$ -defensins in lung host  
 defense and, 709
- Dendritic spines  
 brain disorders, 330–32  
 aging, 329–30  
 mental retardation,  
 330–32  
 neurological disorders,  
 332  
 schizophrenia, 329  
 $Ca^{2+}$  signaling, 334–35  
 Purkinje cell spines,  
 337–38  
 pyramidal cell spines,  
 335–37  
 compartmental models of  
 spine function, 332–34  
 diffusional compartments,  
 332–33  
 electrical compartments,  
 333–34  
 introduction, 313–15  
 motility, 322–23  
 open questions, 340–42  
 structural plasticity  
 experience, 327–28  
 deafferentation-induced  
 plasticity, 322  
 hormonal control,  
 328–29  
 learning, 327–28  
 long-term potentiation,  
 325–27  
 morphological  
 development, 320–22  
 synaptic  
 activity-dependent  
 structural plasticity,  
 323–24  
 structure  
 adult brain, 315–18  
 distributions, 319–20  
 numbers, 319–20  
 relationships with other  
 elements, 319  
 synaptic plasticity  
 calcium handling,  
 338–39
- Dendrotoxin  
 cardiac ion channels and,  
 456
- 15-Deoxy- $\delta^{12-14}$ -  
 prostaglandin  
 J2  
 aromatase and, 102, 117
- 2-Deoxy-D-glucose  
 hypoxia-induced  
 anapnoea and, 273
- Depletion models of  
 depression  
 short-term synaptic  
 plasticity and, 369–75
- Depolarization  
 cardiac ion channels and,  
 431–61
- Desensitization  
 G proteins and olfactory  
 signal transduction, 189,  
 208–9  
 G proteins and pheromone  
 signaling, 129–43  
 short-term synaptic  
 plasticity and, 378–79
- Development  
 dendritic spines and,  
 320–22  
 prolactin and, 55–57  
 renin angiotensin system  
 and kidney development,  
 551
- Diabetes  
 iron accumulation in  
 hereditary  
 hemochromatosis and,  
 663
- Diacylglycerol  
 intracellular signal  
 transport and, 409, 410,  
 412–13, 415–16
- Diarrhea  
 genetic diseases of  
 acid-base transporters  
 and, 899

- DIDS  
 cation-Cl cotransporter phenotypes and, 818  
 hepatocyte chloride channels and, 611, 613-21
- Differential targeting  
 $K^+$  channel ontogeny and, 33
- Diffusional compartments  
 dendritic spines and, 332-33
- 5 $\alpha$ -Dihydroxytestosterone  
 aromatase and, 110, 113
- Diltiazem  
 cardiac ion channels and, 445
- Diprotomers  
 sodium pumping and, 13
- Disc membranes  
 rod
- G proteins and  
 phototransduction, 161-62
- Disintegrins  
 ovulation regulators and, 78, 81
- Dissociation signal  
 G proteins and phototransduction, 162-64
- Distal nephron  
 active  $Ca^{2+}$  absorption in distal nephron and, 529
- Distal renal tubular acidosis  
 genetic diseases of acid-base transporters and, 899, 901-10
- Diuretics  
 cation-Cl cotransporter phenotypes and, 818-20  
 renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 854-55, 857
- Downs' syndrome  
 dendritic spines and, 330
- Downstream consequences
- G proteins and olfactory signal transduction, 189-210
- DPDPE  
 hypoxia-induced anaplyrexia and, 271
- Drift algae  
 MAAs in aquatic organisms and, 231
- Drosophila melanogaster*  
 calmodulin as ion-channel subunit and, 292, 297, 301  
 cardiac ion channels and, 435-36  
 genetic diseases of acid-base transporters and, 909  
 G proteins and pheromone signaling, 138  
 $K^+$  channel ontogeny and, 30  
 renal molecular chaperones and, 504  
 renal organic anionic transporters and, 578  
 short-term synaptic plasticity and, 381, 384-85
- Drug and toxin block  
 cardiac ion channels and, 440
- Drug transport  
 renal organic anionic transporters and, 563-84
- dunce* mutant  
 short-term synaptic plasticity and, 384
- Dysidea herbacea*  
 MAAs in aquatic organisms and, 229, 241
- E**
- eag* mutant  
 cardiac ion channels and, 459  
 $K^+$  channel ontogeny and, 25
- Effectors  
 G proteins and pheromone signaling, 129, 132-35, 140-42  
 G proteins and phototransduction, 156-61, 165-69, 172-80
- Egr-1 zinc finger transcription factor  
 ovulation regulators and, 77
- EIPA  
 cation-Cl cotransporter phenotypes and, 818
- Electrophorus* spp.  
 sodium pumping and, 10
- Electrophysiology  
 cardiac ion channels and, 431-61  
 dendritic spines and, 333-34
- Encainide  
 cardiac ion channels and, 443
- Endoplasmic reticulum  
 hepatocyte chloride channels and, 609, 619, 625  
 $K^+$  channel ontogeny and, 19-37
- Endosomes  
 hepatocyte chloride channels and, 609
- Endothelial nitric oxide synthase (eNOS)  
 regulation of cell specificity, 750-53  
 endothelium, 750-51  
 epithelium, 750-51  
 introduction, 749-50  
 lipid environment, 757-61  
 localization in caveolae, 753-60  
 molecular basis of expression, 751-53  
 protein-protein

- interactions, 760-62
  - regulation in caveolae, 760-68
  - signal transduction, 762-63
  - signaling module, 763-68
  - trafficking, 753-57
  - Endothelium
    - endothelial nitric oxide synthase regulation and, 750-51
  - Enhancement
    - short-term synaptic plasticity and, 356-59, 361-62, 364-65, 367, 379-88
  - Enterohepatic circulation
    - bile-salt transporters and, 635-47
  - Environmental factors
    - ENaC and sodium balance, 877-90
    - G proteins and olfactory signal transduction, 189-210
    - MAAs in aquatic organisms and, 223-52
  - Epilepsy
    - cation-Cl cotransporter phenotypes and, 803, 824-25
  - Epiphyseal closure
    - aromatase and, 93
  - Epithelial  $\text{Ca}^{2+}$  channel (ECaC)
    - active  $\text{Ca}^{2+}$  absorption in distal nephron and, 529
  - Epithelial sodium channel (EnaC)
    - cation-Cl cotransporter phenotypes and, 817
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 848-50, 858, 861
    - sodium balance and aldosterone-dependent sodium transport, 880-81
  - amiloride-sensitive electrogenic sodium transport, 880-83
    - animal models of monogenic human diseases, 884-88
    - biophysical properties of ENaC, 881-82
    - gene inactivation of EnaC subunits in mice, 882-83
    - hypertensive phenotype, 879-80
    - hypotensive phenotype, 879-80
    - introduction, 877-79
    - Liddle's syndrome, 887-88
    - monogenic vs polygenic diseases, 889-90
    - physiological properties of ENaC, 881-82
    - pseudohypoaldosteronism type 1, 884-87
    - salt sensitivity vs salt resistance, 879-80
  - Epithelium
    - bile-salt transporters and, 647-50
    - $\beta$ -defensins in lung host defense and, 709-37
    - endothelial nitric oxide synthase regulation and, 749-51
    - olfactory
      - G proteins and olfactory signal transduction, 190-91
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 845
  - Epistane
    - ovulation regulators and, 79
  - ER $\alpha$  receptor
    - endothelial nitric oxide synthase regulation and, 763, 768
  - Escherichia coli*
    - cation-Cl cotransporter phenotypes and, 809
  - Estradiol
    - aromatase and, 93-94, 109-10, 115, 117-18
    - endothelial nitric oxide synthase regulation and, 749, 762-65, 768
    - ovulation regulators and, 70, 78
  - Estrogen
    - cation-Cl cotransporter phenotypes and, 819
  - Extracellular fluid volume control
    - cation-Cl cotransporter phenotypes and, 803
  - Extragenital synthesis
    - aromatase and, 93-119
  - "Extremophily"
    - MAAs in aquatic organisms and, 242
  - Extrusion mechanisms
    - active  $\text{Ca}^{2+}$  absorption in distal nephron and, 539
- F**
- Familial hyperkalemia with hypertension
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 859-62
  - Familial hypoadosteronism, type I
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 850-51
  - Familial hypomagnesemia
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 863-64
  - Farnesoid X receptor (FXR)



- bile-salt transporters and, 638, 641–42, 646, 649–50
- Fatty acid  $\beta$ -oxidation disorders
- animal models, 495
- biochemical evaluation of symptomatic patients, 491, 494
- carnitine: acylcarnitine translocase deficiency, 485
- carnitine
- palmitoyltransferase I deficiency, 484
- carnitine
- palmitoyltransferase II deficiency, 485
- carnitine uptake defect, 484
- fatty acid metabolism, 478–83
- future trends, 495–96
- hepatic ketogenesis, 481–82, 484
- 3-hydroxy
- 3-methylglutaryl-CoA lyase deficiency, 490
- introduction, 477–78
- isolated long-chain
- L-3-hydroxyacyl-CoA dehydrogenase deficiency, 486–87
- ketogenesis disorders, 490
- lipid mobilization, 478, 480
- long-chain fatty acid
- $\beta$ -oxidation disorders, 485–87
- long-chain fatty acid transport/binding defect, 483–84
- medium- and short-chain
- L-3 hydroxyacyl-CoA dehydrogenase deficiency, 488–89
- medium-chain acyl-CoA dehydrogenase deficiency, 487–88
- medium-chain fatty acid
- $\beta$ -oxidation disorders, 487–89
- medium-chain
- 3-ketoacyl-CoA thiolase deficiency, 489
- methods of investigation, 491–95
- miscellaneous fatty acid oxidation disorders, 489
- mitochondrial fatty acid transport disorders, 479, 484
- newborn screening, 491
- plasma membrane, 478, 480, 483
- postmortem screening, 494–95
- prenatal diagnosis, 491
- primary disorders of respiration, 490–91
- short-chain fatty acid
- $\beta$ -oxidation disorders, 489
- trifunctional protein deficiency, 486–87
- unspecified disorders, 495–96
- very-long-chain acyl-CoA dehydrogenase deficiency, 485–86
- Fertility
- prolactin and, 57
- Fgf-9* gene
- ovulation regulators and, 82
- Fishes
- MAAs in aquatic organisms and, 243–44
- Flecainide
- cardiac ion channels and, 443–44, 447, 456
- Fludrocortisone
- cation-Cl cotransporter phenotypes and, 818
- Follicle-stimulating hormone (FSH)
- aromatase and, 99–100, 109–10, 114
- ovulation regulators and, 69–70, 78–79
- Formycin triphosphate (FTP)
- sodium pumping and, 12
- Forskolin
- ovulation regulators and, 78
- Fragile X syndrome
- dendritic spines and, 313, 330–32
- Frizzled* gene
- ovulation regulators and, 82–84
- Functional bipartition
- calmodulin as ion-channel subunit and, 289, 302–4
- Functional duality
- K<sup>+</sup> channel ontogeny and, 35
- Fungi
- $\beta$ -defensins in lung host defense and, 709
- MAAs in aquatic organisms and, 226, 239–40
- Furosemide
- cation-Cl cotransporter phenotypes and, 812, 817, 820
- G**
- G $\beta$ 5L protein
- G proteins and phototransduction, 176–80
- Gadusols
- MAAs in aquatic organisms and, 223–52
- Gain-of-function mutations
- cation-Cl cotransporter phenotypes and, 821–22
- ENaC and sodium balance, 877, 880
- Gases
- hypoxia-induced



- anapryxia and, 271-76
- Gating  
 calmodulin as ion-channel subunit and, 289, 293-94  
 cardiac ion channels and, 440, 453-54, 459  
 G proteins and olfactory signal transduction, 201-4  
 hepatocyte chloride channels and, 609, 621, 625-26
- Gelatinases  
 ovulation regulators and, 75
- Gene disruption  
 cation-Cl cotransporter phenotypes and, 808, 816-18, 820-21, 824, 827-28
- Gene inactivation  
 ENaC and sodium balance, 882-83
- Gene targeting  
 GM-CSF regulation of lung functions and, 788-89
- Gene transposition  
 G proteins and olfactory signal transduction, 189-210
- GIRK proteins  
 cardiac ion channels and, 457
- Gitelman's syndrome  
 cation-Cl cotransporter phenotypes and, 803, 820  
 ENaC and sodium balance, 880  
 renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845, 854-57, 864-65
- Glia  
 short-term synaptic plasticity and, 377-78
- Glomerulonephritis  
 renal molecular chaperones and, 514-15
- Glucocorticoid remediable  
 aldosteronism  
 renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 850-51
- Glucocorticoids  
 aromatase and, 100-1, 107  
 ENaC and sodium balance, 877, 881  
 renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845-66
- Glucose  
 aromatase and, 109-10, 115
- Glutamic acid-rich proteins (GARPs)  
 G proteins and phototransduction, 172-73
- Glycosylation  
 $K^+$  channel ontogeny and, 21-22, 30
- Glynn IM, 1-14
- GM $^{-/-}$  mice  
 GM-CSF regulation of lung functions and, 785-86, 789-91
- Golgi complex  
 hepatocyte chloride channels and, 609, 619, 625
- Gonadotrophins  
 aromatase and, 96, 100, 109, 114
- Gordon's syndrome  
 ENaC and sodium balance, 880
- GPA1 protein  
 G proteins and pheromone signaling, 129
- G protein-coupled receptors  
 endothelial nitric oxide synthase regulation and, 749, 762, 768
- G proteins  
 cardiac ion channels and, 458
- intracellular signal transport and, 407, 409, 419, 421-23
- $K^+$  channel ontogeny and, 24-25, 33, 37
- olfactory signal transduction and adenylyl cyclases, 198-99  
 $Ca^{2+}$  conductance, 204, 207-8  
 $Ca^{2+}$ -dependent  $Cl^-$  conductance, 203, 207-8
- cAMP, 197-98
- cellular composition of olfactory epithelium, 190-91
- cGMP, 205-7  
 channels, 200  
 conclusions, 210  
 cyclic nucleotide gated channels, 201-4  
 desensitization, 208-9
- G proteins, 196
- general features, 191-92
- inositol triphosphate, 204-5
- introduction, 189-90
- $K^+$  conductance, 203-4
- long-term responses to odorant detection, 209-10
- miscellaneous systems, 203-4
- $Na^+$  conductance, 204
- odorant-binding proteins, 193
- phosphodiesterases, 199-200
- receptors, 193-96
- regulation, 202-3
- transduction cascade components, 193-200, 204-8
- ovulation regulators and, 80

- pheromone signaling and  
AKR1, 137-40  
ASG7, 137-40  
CDC24, 132-35  
conclusions, 142-43  
effectors, 132  
MPT5, 137-40  
perspectives, 129-31  
PLP1/2, 137-40  
posttranslational  
modification, 135-37  
regulation, 131-32,  
135-40  
scope, 129-31  
SST2, 137-42  
STE5, 132-35  
STE20, 132-35  
yeast, 131-32, 140-42
- phototransduction and  
activation phase of  
vertebrate  
phototransduction,  
155-56  
adaptational changes,  
170-73  
amplification, 154-55,  
157-60, 170-73  
amplified transient  
signal, 165-67  
binding signals, 162-64  
biochemical  
measurements, 160-70  
catalytic domain, 178  
conclusions, 180  
cyclic GMP hydrolysis  
and cGMP-channel  
closure, 156  
dissociation signals,  
162-65  
dual regulation, 177-78  
effector enzyme status,  
168  
electrophysiological  
measurements, 169-70  
GARPs, 172-73  
G<sub>i</sub>-phosphodiesterase  
interaction, 165-67
- infrared light scattering,  
161-67  
introduction, 153-57  
Michaelis constant,  
168-69  
near infrared light  
scattering, 162  
noncatalytic domain,  
178  
PDE $\gamma$ , 176-77  
phosducin, 172  
phosphodiesterase,  
160-70  
photoisomerization, 156  
R\*, 160-67  
reconciliation of  
biochemical and  
electrophysiological  
measurements, 169-70  
release signal, 165-67  
RGS9, 175-76  
RGS9-G $\beta$ 5L, 176-80  
rod disc membranes,  
161-62  
termination of  
phototransduction,  
156-57  
signal transduction  
timing, 154-55  
transducin, 156, 160-70,  
172-80  
transducin  
GTPase-regulating  
proteins, 174-75,  
177-78  
turnover rate, 168-69  
vertebrate rod  
phototransduction,  
154-55  
vG estimation, 164-65
- Granulocyte/macrophage-  
colony-stimulating  
factor (GM-CSF)  
regulation of lung  
functions and  
alveolar macrophages,  
785-86, 788-92
- autoimmunity, 787  
GM<sup>-/-</sup> mice, 785-86,  
789-91  
GM-CSF, 776-77,  
786-91  
GM R $\beta$ c<sup>-/-</sup> mice,  
790-91  
host defense  
abnormalities, 790-91  
increased lung size, 785  
introduction, 775-76  
PU.1, 791-93  
pulmonary alveolar  
proteinoses, 782-90,  
793  
pulmonary surfactant  
composition and  
function, 777-81  
regulation of multiple  
functions, 789  
signal transduction,  
777-83  
surfactant homeostasis,  
777-83  
SPC-GM<sup>+/+</sup>/CM<sup>-/-</sup>  
mice, 785  
SP-D, 786  
summary, 793  
surfactant metabolism,  
781-82, 785  
surfactant phospholipid  
and protein clearance,  
789  
transcriptional control,  
791  
type II cell hyperplasia,  
785
- Granulosa cells  
aromatase and, 99, 103  
ovulation regulators and,  
69-84
- Guanosine triphosphate  
(GTP)  
G proteins and  
phototransduction, 153,  
156, 160-61, 165-66,  
171, 173

*Gymnodinium sanguineum*  
MAAs in aquatic  
organisms and, 238

## H

H<sup>+</sup>  
renal genetic disorders  
related to K<sup>+</sup> and Mg<sup>2+</sup>,  
856

H<sup>+</sup>-ATPase  
genetic diseases of  
acid-base transporters  
and, 899, 907-11

*H63D* mutant  
iron accumulation in  
hereditary  
hemochromatosis and,  
668-69

Harderian gland  
prolactin and, 57

HCN proteins  
cardiac ion channels and,  
459

Heat shock proteins  
renal molecular chaperones  
and, 503-18

Hemochromatosis  
hereditary, 663-74

Hemoglobin  
cation-Cl cotransporter  
phenotypes and, 822-23  
hypoxia-induced  
anapryxia and, 263-79

Hepatocellular carcinoma  
iron accumulation in  
hereditary  
hemochromatosis and,  
663

Hepatocytes  
bile-salt transporters and,  
638-47  
trafficking of canalicular  
ABC transporters and,  
595-605

Hepcidin  
iron accumulation in  
hereditary

hemochromatosis and,  
663, 665

Hereditary hemochromatosis  
iron accumulation in  
communication between  
sites of iron storage and  
uptake, 665-66  
cultured cells, 671-72  
dietary iron absorption,  
672-73  
forms of  
hemochromatosis, 674  
hepatic iron storage, 665  
*HFE* gene  
*C282Y* mutant,  
667-68  
gene and transcript,  
666-67  
gene product, 667  
*H63D* mutant, 668-69  
*Hfe* disruption,  
673-74  
*HFE* protein, 669-74  
murine *Hfe*, 673-74  
mutations, 667-70,  
672

introduction, 663-64  
iron absorption, 664  
 $\beta_2$ -microglobulin, 669  
regulation of  
homeostasis, 664  
reticuloendothelial iron  
storage, 665  
summary, 674  
transferrin receptor,  
669-72

HERG channel  
cardiac ion channels and,  
448-53, 455, 459  
K<sup>+</sup> channel ontogeny and,  
25

Heterosynaptic inhibition  
short-term synaptic  
plasticity and, 376

*HFE* gene  
iron accumulation in  
hereditary

hemochromatosis and,  
663

High-altitude pulmonary  
edema  
ENaC and sodium balance,  
887, 890

High-density lipoprotein  
(HDL)  
aromatase and, 114  
endothelial nitric oxide  
synthase regulation and,  
749, 757-61, 764-66

Histamine  
hypoxia-induced  
anapryxia and, 271

Homeostasis  
bile-salt transporters and,  
635-36, 638, 651  
ENaC and sodium  
balance, 888  
GM-CSF regulation of  
lung functions and,  
775-93  
iron accumulation in  
hereditary  
hemochromatosis and,  
663-64  
renal genetic disorders  
related to K<sup>+</sup> and Mg<sup>2+</sup>,  
845-66

Homosynaptic inhibition  
short-term synaptic  
plasticity and, 375-76

Host defense  
GM-CSF regulation of lung  
functions and, 775-93

Human chorionic  
gonadotropin (hCG)  
ovulation regulators and,  
79

Human Genome Project  
aromatase and, 95

Hyaluronic acid  
ovulation regulators and,  
71-74

Hydronephrosis  
renin angiotensin system

- and kidney development, 45–52
  - 3-Hydroxy
    - 3-methylglutaryl-CoA lyase deficiency
    - fatty acid  $\beta$ -oxidation disorders and, 490
  - Hyperplasia
    - type II
      - GM-CSF regulation of lung functions and, 785
  - Hyperpolarization
    - active  $\text{Ca}^{2+}$  absorption in distal nephron and, 529
  - Hypertension
    - cation-Cl cotransporter phenotypes and, 810, 812
    - ENaC and sodium balance, 877–79, 881, 886, 888–89
    - endothelial nitric oxide synthase regulation and, 749
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 845, 848
  - Hypoadosteronism
    - renal genetic disorders related to  $\text{K}^{+}$  and  $\text{Mg}^{2+}$ , 850–51, 857–59
  - Hypocalciurea
    - active  $\text{Ca}^{2+}$  absorption in distal nephron and, 540
  - Hypotension
    - ENaC and sodium balance, 879
  - Hypothermia
    - hypoxia-induced anapnoea and, 263–79
  - Hypoxia
    - renal molecular chaperones and, 503
  - Hypoxia-induced anapnoea
    - adenosine, 270
    - arginine vasopressin, 268–69
    - carbon monoxide, 274–76
    - conclusions, 277–79
    - cyclic nucleotides, 276–77
    - endogenous opioids, 271
    - gases, 271–76
    - histamine, 271
    - introduction, 263–64
    - lactate, 269–70
    - mechanisms, 266–67
    - nitric oxide, 272–74
    - protective response, 265–66
    - putative mediators, 268–76
    - thermoregulatory set point, 264–65
- I**
- IK channels
    - calmodulin as ion-channel subunit and, 296–97
  - $\text{I}_{\text{Kr}}$  delayed rectifier currents
    - cardiac ion channels and, 448, 453–57
  - Immune-mediated injury
    - renal molecular chaperones and, 514–15
  - Impotence
    - iron accumulation in hereditary hemochromatosis and, 663
  - Indomethacin
    - cation-Cl cotransporter phenotypes and, 817
  - Infertility
    - male
      - cation-Cl cotransporter phenotypes and, 810
  - Inflammatory-like response
    - ovulation and, 69–84
  - Infrared light scattering
    - G proteins and phototransduction, 161–67
  - Innate defense
    - $\beta$ -defensins in lung host defense and, 709–37
    - GM-CSF regulation of lung functions and, 775–93
  - Inositol triphosphate ( $\text{IP}_3$ )
    - calmodulin as ion-channel subunit and, 295–96
  - G proteins and olfactory signal transduction, 204–5
  - Insulin
    - aromatase and, 109–10, 115
    - ENaC and sodium balance, 880
    - hypoxia-induced anapnoea and, 273
  - Insulin-like growth factor 1 (IGF-1)
    - aromatase and, 110
    - ovulation regulators and, 70
  - Integrins
    - ovulation regulators and, 80
  - Inter- $\alpha$ -trypsin inhibitor
    - ovulation regulators and, 71
  - Interleukins
    - aromatase and, 96, 106
  - Intestinal phenotype
    - cation-Cl cotransporter phenotypes and, 809
  - Intracellular compartments
    - hepatocyte chloride channels and, 609, 618–25
  - Intracellular signal transport
    - AKAPs, 420–21
    - anchoring proteins, 409, 410–21, 423
    - cardiac channel activation, 414–15
    - ischemic injury, 415–17
    - location, 407–9
    - L-type  $\text{Ca}^{2+}$  channels, 420–21
    - myocyte contraction rate, 415–16
    - overview, 407–9
    - perspectives, 423
    - $\delta\text{PKC}$ , 416–18
    - $\epsilon\text{PKC}$ , 415–16

- protein kinase A, 420–21  
 protein kinase C, 414–17  
 Rab GTPases, 421–23  
 subcellular transport, 409–14  
 substrate specificity, 409–14  
 trafficking, 421–23  
 transgenic studies of cardiac PKC, 417–19  
 translocation, 407–19  
 translocation modifiers, 417–19
- Intracrine action  
 aromatase and, 93, 116
- Inward rectifiers  
 cardiac ion channels and, 457–58  
 K<sup>+</sup> channel ontogeny and, 28–29
- Ion channels  
 active Ca<sup>2+</sup> absorption in distal nephron and, 529  
 calmodulin as ion-channel subunit and, 289–305  
 cardiac ion channels and, 431–61  
 dendritic spines and, 313, 334–41  
 ENaC and sodium balance, 877–90  
 G proteins and olfactory signal transduction, 200–4  
 hepatocyte chloride channels and, 609–26  
 intracellular signal transport and, 420–21  
 renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 845–66  
 renal organic anionic transporters and, 563–84  
 short-term synaptic plasticity and, 355–88
- Ionomycin  
 endothelial nitric oxide synthase regulation and, 767
- Ionotropic receptors  
 presynaptic short-term synaptic plasticity and, 376–77
- Ischemia  
 intracellular signal transport and, 415–17  
 renal molecular chaperones and, 503, 507–12
- Isoproterenol  
 cardiac ion channels and, 452, 454, 460
- I<sub>TO</sub> transient outward current  
 cardiac ion channels and, 447–48
- J**  
 JAK1/STAT3 pathway  
 aromatase and, 100–1
- K**  
 K<sup>+</sup>  
 calmodulin as ion-channel subunit and, 296–97  
 cardiac ion channels and, 433, 435–36, 438, 440, 451–53, 457, 459–60  
 G proteins and olfactory signal transduction, 200–4  
 G proteins and phototransduction, 155  
 renal genetic disorders related to, 845–66  
 sodium pumping and, 1–13  
 K<sup>+</sup> channel ontogeny  
 auxiliary subunits, 27–31  
 biogenesis, 20–31  
 Ca-activated K<sup>+</sup> channels, 28  
 cellular distribution, 34–35  
 chaperones, 23–24  
 clustering, 33–34  
 crosstalk with plasma membrane, 36–37  
 cytosolic export/targeting motifs, 32  
 degradation, 31  
 differential targeting to lipid rafts, 33  
 functional duality, 35  
 future research, 34–37  
 glycosylation, 21–22  
 integration, 22–35  
 introduction, 19  
 inward rectifying channels, 28–29  
 KIR channels, 28–29  
 Kv channels, 29–30  
 late recognition, 36  
 modification, 21–22  
 oligomerization, 24  
 oxidation, 22  
 plasma membrane insertion/retrieval, 34–35  
 protein folding, 27  
 putative modifiers, 22  
 recognition domains, 24–25  
 regulation, 34–35  
 sorting, 31–34  
 stoichiometry, 34–35  
 subunit composition, 32–35  
 targeting, 20  
 temporal sequence clues, 36  
 tetramer formation, 25–27  
 topogenic duality, 35  
 trafficking, 31–34  
 translocation, 20–21
- KCC2 cotransporter  
 cation-Cl cotransporter phenotypes and, 823–26
- KCC3 cotransporter  
 cation-Cl cotransporter phenotypes and, 803, 826–29
- KCC1 cotransporter  
 cation-Cl cotransporter phenotypes and, 822–23
- KChAP protein

- $K^+$  channel ontogeny and, 23–24  
 K-Cl cotransporter  
   cation-Cl cotransporter phenotypes and, 803  
*KCNE* genes  
   cardiac ion channels and, 448, 460  
 Ketogenesis  
   fatty acid  $\beta$ -oxidation disorders and, 477, 481–82, 484, 490  
 Kidneys  
   active  $Ca^{2+}$  absorption in distal nephron and, 529  
   cation-Cl cotransporter phenotypes and, 803–43  
   ENaC and sodium balance, 877  
   genetic diseases of  
     acid-base transporters and, 899–916  
   renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845–66  
   renal organic anionic transporters and, 563–84  
   renin angiotensin system and, 51  
 KIR channels  
   cardiac ion channels and, 457–58  
    $K^+$  channel ontogeny and, 25, 28–29, 32–35  
 Knockouts  
   aromatase and, 94, 111–14  
   bile-salt transporters and, 641–42  
   hypoxia-induced anapryxia and, 274  
   iron accumulation in hereditary hemochromatosis and, 663  
   renin angiotensin system and kidney development, 551  
 KST1 channel  
    $K^+$  channel ontogeny and, 25  
 Kv channels  
    $K^+$  channel ontogeny and, 19–22, 29–30  
*KvLQT1* gene  
   cardiac ion channels and, 453–55, 460  
**L**  
 Lactate  
   hypoxia-induced anapryxia and, 263, 269–70  
 Lactation  
   prolactin and, 47–60  
*Laminaria saccharina*  
   MAAs in aquatic organisms and, 238  
 Laminin  
   ovulation regulators and, 76  
 Late recognition  
    $K^+$  channel ontogeny and, 36  
*latheo* mutant  
   short-term synaptic plasticity and, 385  
 Leptin  
   aromatase and, 114  
   ovulation regulators and, 70  
 Liddle's syndrome  
   ENaC and sodium balance, 877–78, 880–81, 885, 887–88  
   renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845, 848–49  
 Lidocaine  
   cardiac ion channels and, 441  
 Light  
   G proteins and phototransduction, 153–80  
 Lipid homeostasis  
   bile-salt transporters and, 635  
 Lipid mobilization  
   fatty acid  $\beta$ -oxidation disorders and, 478, 480  
 Lipid rafts  
    $K^+$  channel ontogeny and, 33  
 Lipids  
   aromatase and, 93–119  
*Lissoclinum patella*  
   MAAs in aquatic organisms and, 228  
 Lithium  
   sodium pumping and, 11–12  
 Liver  
   aromatase and, 96, 108, 115  
   bile-salt transporters and, 635–47  
   fatty acid  $\beta$ -oxidation disorders and, 481–82, 484  
   hepatocyte chloride channels and, 609–26  
   iron accumulation in hereditary hemochromatosis and, 663–74  
   trafficking of canalicular ABC transporters in hepatocytes and, 595–605  
 L-NAME  
   hypoxia-induced anapryxia and, 272–73  
*Lobophytum compactum*  
   MAAs in aquatic organisms and, 232–40  
 Local estrogen biosynthesis  
   aromatase and, 115–19  
 Long-chain fatty acids (LCFAs)  
   fatty acid  $\beta$ -oxidation disorders and, 478–81, 483–87

- Long-chain fatty acid  
 transport/binding defect  
 fatty acid  $\beta$ -oxidation  
 disorders and, 483-84
- Long-chain  
 L-3-hydroxyacyl-CoA  
 dehydrogenase  
 deficiency  
 isolated  
 fatty acid  $\beta$ -oxidation  
 disorders and, 486-87
- Long QT syndrome  
 cardiac ion channels and,  
 436-37, 442-43, 450-55,  
 461
- Long-term potentiation  
 dendritic spines and,  
 325-27
- Loop diuretics  
 renal genetic disorders  
 related to  $K^+$  and  $Mg^{2+}$ ,  
 855
- Loss-of-function mutations  
 cation-Cl cotransporter  
 phenotypes and, 803, 818  
 ENaC and sodium balance,  
 877, 884
- Low-density lipoprotein  
 (LDL)  
 aromatase and, 109  
 endothelial nitric oxide  
 synthase regulation and,  
 749, 757-61, 765-66
- L-type  $Ca^{2+}$  channels  
 intracellular signal  
 transport and, 420-21
- Lung cancer  
 molecular pathogenesis of  
*AIS*, 686  
*APC/wnt* pathway,  
 690-91  
 autocrine factors,  
 682-84  
*BCL-2*, 685  
 conclusions, 697-98  
 dominant oncogenes,  
 684-86  
 frequent allele loss,  
 686-93  
 growth factors and their  
 receptors, 682-84  
 introduction, 681-82  
 microsatellites, 694-95  
*MYC*, 685  
 neuroendocrine  
 phenotype, 695  
*Notch-3*, 685-86  
*p16<sup>INK4</sup>*-cyclin  
 D1-CDK4-*RB* pathway,  
 689-90  
*p53*, 688-89  
 paracrine factors,  
 682-84  
 prognostic markers, 697  
 promoter methylation,  
 691  
*RAS*, 684-85  
 second primary lung  
 cancers, 696-97  
 smoke-damaged  
 respiratory epithelium,  
 693-94  
 telomerase, 695  
 tobacco smoke  
 carcinogens, 693-97  
 tumor angiogenesis,  
 691-93  
 tumor suppressor genes,  
 686-93  
 viral factors, 695-96
- Lungs  
 $\beta$ -defensins in lung host  
 defense and, 709-37  
 ENaC and sodium balance,  
 877  
 endothelial nitric oxide  
 synthase regulation and,  
 749  
 GM-CSF regulation of lung  
 functions and, 775-93
- Luo-Rudy formalism  
 cardiac ion channels and,  
 434
- Luteinizing hormone (LH)  
 aromatase and, 109-10,  
 114  
 ovulation regulators and,  
 69-84
- Lysosomes  
 hepatocyte chloride  
 channels and, 609,  
 618-19
- M**
- Macroalgae  
 MAAs in aquatic  
 organisms and, 227-28
- $\alpha_2$ -Macroglobulin  
 ovulation regulators and,  
 79
- Macrophage-mediated innate  
 host defense  
 GM-CSF regulation of lung  
 functions and, 775-93
- Magnesium wasting  
 renal genetic disorders  
 related to  $K^+$  and  $Mg^{2+}$ ,  
 864-65
- Male fertility  
 cation-Cl cotransporter  
 phenotypes and, 810  
 prolactin and, 57
- Mammary gland  
 prolactin and, 47, 52,  
 55-56, 59
- Marine organisms  
 MAAs in aquatic  
 organisms and, 224-26,  
 243-44
- Mastocarpus stellatus*  
 MAAs in aquatic  
 organisms and, 249
- Mechanical coupling  
 $Ca^{2+}$  sensor and  
 calmodulin as  
 ion-channel subunit  
 and, 301-2
- Medium- and short-chain L-3  
 hydroxyacyl-CoA  
 dehydrogenase  
 deficiency

- fatty acid  $\beta$ -oxidation disorders and, 488–89
- Medium-chain acyl-CoA dehydrogenase deficiency
- fatty acid  $\beta$ -oxidation disorders and, 487–88
- Medium-chain fatty acid  $\beta$ -oxidation disorders
- fatty acid  $\beta$ -oxidation disorders and, 487–89
- Medium-chain 3-ketoacyl-CoA thiolase deficiency
- fatty acid  $\beta$ -oxidation disorders and, 489
- Membrane transport
- fatty acid  $\beta$ -oxidation disorders and, 477
- Mental retardation
- dendritic spines and, 330–32
- genetic diseases of acid-base transporters and, 899
- Metabolism
- aromatase and, 93–119
- genetic diseases of acid-base transporters and, 899, 914
- GM-CSF regulation of lung functions and, 781–85
- iron accumulation in hereditary hemochromatosis and, 663–74
- prolactin and, 57–58
- Metabotropic receptors
- short-term synaptic plasticity and, 375–76
- Metalloproteinases
- ovulation regulators and, 74–79
- Metarhodopsin II
- G proteins and phototransduction, 156–62, 164–67, 169, 171–73, 177
- METH-1* gene
- ovulation regulators and, 78
- Metzincins
- ovulation regulators and, 78
- Mg<sup>2+</sup>
- renal genetic disorders related to, 845–66
- Micelles
- bile-salt transporters and, 635
- Michaelis constant
- G proteins and phototransduction, 159, 168–69
- Microalgae
- MAAs in aquatic organisms and, 227–28
- Micrococcus* spp.
- MAAs in aquatic organisms and, 227
- $\beta_2$ -Microglobulin
- iron accumulation in hereditary hemochromatosis and, 669
- Microsatellites
- ENaC and sodium balance, 879
- lung cancer molecular pathogenesis and, 694–95
- Mid-1 related chloride channel (MCLC)
- hepatocyte chloride channels and, 609, 625–26
- Mineralocorticoids
- cation-Cl cotransporter phenotypes and, 818–19
- ENaC and sodium balance, 881–82, 884
- renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 845, 849–50
- minK* (*isk*) mutant
- cardiac ion channels and, 448, 453–55
- cation-Cl cotransporter phenotypes and, 808–9
- MiRP1* gene
- cardiac ion channels and, 448, 453, 460
- Mitochondria
- cardiac ion channels and, 458
- fatty acid  $\beta$ -oxidation disorders and, 477–96
- hepatocyte chloride channels and, 609, 621, 626
- Mixed renal tubular acidosis
- genetic diseases of acid-base transporters and, 914–15
- MMP* genes
- ovulation regulators and, 74–79
- Monogenic human diseases
- ENaC and sodium balance, 877–90
- Montastraea* spp.
- MAAs in aquatic organisms and, 228, 247
- Montipora verrucosa*
- MAAs in aquatic organisms and, 239
- MPT5 protein
- G proteins and pheromone signaling, 137–40
- Mrp proteins
- bile-salt transporters and, 635, 640, 644, 646–47, 650
- renal organic anionic transporters and, 563, 574–76
- Multidrug resistance proteins
- renal organic anionic transporters and, 563–76
- Multiple site hypotheses
- short-term synaptic



- plasticity and, 364–67
- Multivesicular release  
short-term synaptic  
plasticity and, 373
- MVDP protein  
ovulation regulators and,  
76
- MYC proto-oncogenes  
lung cancer molecular  
pathogenesis and, 685
- Mycosporine-like amino  
acids (MAAs)  
aquatic organisms and  
algal-invertebrate  
symbioses, 228–29  
antioxidant functions,  
233–35  
asymbiotic invertebrates  
and vertebrates, 229–30  
bathymetric distribution,  
230–31  
bioaccumulation of  
MAAs by consumer  
organisms, 249–51  
biochemical defenses,  
223–24  
biosynthesis of MAAs  
by algal producers,  
245–49  
conclusions, 251  
coral bleaching, 240–41  
discovery, 224–26  
distribution, 226–33  
freshwater organisms,  
233  
future research, 251–52  
gadusols, 233–43  
geographic occurrence,  
231–32  
historical context,  
224–26  
interconversion of  
dietary MAAs, 251  
marine macroalgae,  
227–28  
marine organisms,  
224–26
- marine vision, 243–44  
occurrence, 226–33  
ocular tissues of fishes,  
243–44  
osmotic regulation,  
242–43  
outlook, 251–52  
protective functions,  
233–43  
regulation, 247–49  
reproductive regulation,  
241–42  
seasonal occurrence,  
231–32  
shikimate pathway,  
245–49  
stimulation, 247–49  
structure/function  
relationships, 235–37  
terrestrial functions, 233  
terrestrial fungi, 226  
uptake, 249  
UV suncreening,  
233–35
- Myocytes  
cardiac ion channels and,  
431–61
- myr*-mutant  
endothelial nitric oxide  
synthase regulation and,  
756, 765
- N**
- Na<sup>+</sup>  
cardiac ion channels and,  
435–36, 438–44, 447, 459  
ENaC and sodium balance,  
877–90  
G proteins and olfactory  
signal transduction, 200–4  
G proteins and  
phototransduction, 155  
history of research, 1–14  
renal genetic disorders  
related to K<sup>+</sup> and Mg<sup>2+</sup>,  
845–66  
Na<sup>+</sup>-bicarbonate  
cotransporter  
genetic diseases of  
acid-base transporters  
and, 899–916  
Na<sup>+</sup>/Ca<sup>2+</sup> exchanger  
active Ca<sup>2+</sup> absorption in  
distal nephron and,  
529–30  
Na-Cl cotransporters  
cation-Cl cotransporter  
phenotypes and, 803,  
818–22  
Na<sup>+</sup>-dependent  
cotransporters  
cation-Cl cotransporter  
phenotypes and, 806–21  
NADPH-cytochrome P450  
reductase  
aromatase and, 94, 97–99  
Na<sup>+</sup>-independent K-Cl  
cotransporters  
cation-Cl cotransporter  
phenotypes and, 822–29  
Na,K-ATPase  
sodium pumping and, 1,  
6–13  
Na-K-2Cl transporter  
cation-Cl cotransporter  
phenotypes and, 803,  
806–18  
Naloxane  
hypoxia-induced  
anapnyxia and, 271  
Na<sup>+</sup>-taurocholate  
cotransporters  
bile-salt transporters and,  
635, 638–42  
*NBC1* mutations  
genetic diseases of  
acid-base transporters  
and, 913–14  
NCC cotransporter  
cation-Cl cotransporter  
phenotypes and, 803  
Near-infrared light scattering  
G proteins and  
phototransduction, 162

- Necturus* spp.  
 cation-Cl cotransporter phenotypes and, 827
- Nephrocalcinosis  
 renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 863
- Nephrotoxins  
 renal molecular chaperones and, 503, 512–14
- Nethyl *N*-ethyl maleimide  
 sodium pumping and, 13
- Neuroendocrine phenotype  
 lung cancer molecular pathogenesis and, 695
- Neurological disorders  
 dendritic spines and, 332
- Neurons  
 cation-Cl cotransporter phenotypes and, 803, 812, 825–26  
 dendritic spines and, 313–42  
 G proteins and olfactory signal transduction, 189–210
- Neuropathies  
 cation-Cl cotransporter phenotypes and, 828–29
- Neurotransmitters  
 dendritic spines and, 313  
 short-term synaptic plasticity and, 369–76
- Newborn screening  
 fatty acid  $\beta$ -oxidation disorders and, 491
- $Ni^{+}$   
 cardiac ion channels and, 445
- Nifedipine  
 cardiac ion channels and, 445
- Nitric oxide  
 hypoxia-induced anapylrexia and, 263, 271–74
- Nitric oxide synthase  
 endothelial, 749–68
- 7-Nitroindazole  
 hypoxia-induced anapylrexia and, 274
- NKCC1 cotransporter  
 cation-Cl cotransporter phenotypes and, 806–12
- NKCC2 cotransporter  
 cation-Cl cotransporter phenotypes and, 803, 813–18
- NMDA receptor  
 calmodulin as ion-channel subunit and, 294–95  
 dendritic spines and, 313, 318, 324, 328–39  
 short-term synaptic plasticity and, 380
- Nostoc commune*  
 MAAs in aquatic organisms and, 227
- Notch-3* oncogene  
 lung cancer molecular pathogenesis and, 685–86
- NPPB  
 hepatocyte chloride channels and, 611, 613–14, 617–18, 620–21
- NPT protein  
 renal organic anionic transporters and, 563, 573–74
- Ntcp proteins  
 bile-salt transporters and, 635, 638–42
- N-terminal domains  
 active  $Ca^{2+}$  absorption in distal nephron and, 529
- Nuclear membrane  
 hepatocyte chloride channels and, 619–20
- Nucleus  
 cellular  
 hepatocyte chloride channels and, 609  
 prolactin and, 51–52
- O**
- OBP proteins  
 G proteins and olfactory signal transduction, 193
- Obstructive nephropathy  
 renal molecular chaperones and, 514
- OCTN2* gene  
 fatty acid  $\beta$ -oxidation disorders and, 479
- Odorant transduction  
 G proteins and olfactory signal transduction, 189–210
- ODQ  
 hypoxia-induced anapylrexia and, 273, 275
- 1,25-(OH) $_2$ D $_3$   
 active  $Ca^{2+}$  absorption in distal nephron and, 529–30
- Olfaction  
 G proteins and, 189–210
- Oligomerization  
 $K^+$  channel ontogeny and, 19, 24–27, 35–36
- Oligomycin  
 sodium pumping and, 10
- Oncostatin M  
 aromatase and, 96, 117
- Oocyte microenvironment  
 ovulation regulators and, 70–75
- Opioids  
 hypoxia-induced anapylrexia and, 263, 271
- Organic anion transporting polypeptide (OATP)  
 bile-salt transporters and, 635, 639, 642–44, 648  
 renal anionic drug transport and  
 apical transport, 565, 572, 582  
 ATP-binding cassette subfamily ABCC, 574–75

- basolateral transport, 565, 581  
 cloning, 572-78  
 conclusions, 583-84  
 functional model of renal organic anion transport, 565-72  
 intracellular disposition, 582-83  
 introduction, 563-65  
 molecular characteristics of transporters, 566-71  
 multidrug resistance proteins MRP1-MRP6, 574-76  
 NPT1, 573-74  
 OAT1-OAT4, 572  
 PDZ domain-containing proteins, 578-81  
 peptide transporters PEPT1-PEPT2, 578  
 regulation, 581-83  
 sodium/phosphate cotransporter type 1, 573-74  
 solute carrier family 22A, 572, 573  
 solute carrier family SCL15A, 578  
 solute carrier family SCL22A, 576-78  
 targeting prediction, 579  
 Orthophosphate sodium pumping and, 1, 8, 10, 13  
*Oryzias latipes* MAAs in aquatic organisms and, 249  
*Oscillatoria spongeliae* MAAs in aquatic organisms and, 229  
 Osmotic regulation MAAs in aquatic organisms and, 223, 242, 243  
 renal molecular chaperones and, 503, 516-18
- Osteopetrosis genetic diseases of acid-base transporters and, 899, 910-11  
 Ouabain ENaC and sodium balance, 881  
 pumping and, 8  
 Ovaries aromatase and, 96, 98-100, 116-17  
 ovulation regulators and, 69-84  
 Ovulation new regulators of *ADAMTS-1* gene, 78-82  
*Cathepsin L* gene, 78-82  
 cumulus expansion, 71-75  
*Frizzled* gene, 82-84  
 granulosa compartment, 77-82  
 introduction, 69-70  
 LH-regulated genes, 75-84  
 oocyte microenvironment, 71-75  
 preovulatory follicle, 70-71  
 progesterone, 78-82  
 progesterone-regulated genes, 78-82  
 theca cell compartment, 75-77  
*Wnts* gene, 82-84  
 Oxidation  $K^+$  channel ontogeny and, 22  
 Oxygen hypoxia-induced anapryxia and, 263-79
- P**  
*p16<sup>INK4</sup>*-cyclin D1-CDK4-*RB* pathway lung cancer molecular pathogenesis and, 689-90  
*p53* gene lung cancer molecular pathogenesis and, 688-89  
 P450arom gene product aromatase and, 94, 97-99  
 Pacemaker channels cardiac ion channels and, 458-59  
 Pain perception cation-Cl cotransporter phenotypes and, 803  
*Palmaria palmata* MAAs in aquatic organisms and, 226  
*palm*-mutant endothelial nitric oxide synthase regulation and, 756-57  
*Palyotha tuberculosis* MAAs in aquatic organisms and, 226  
*pantophobiac* mutants calmodulin as ion-channel subunit and, 293  
 PAPIII protein ovulation regulators and, 84  
 Paracrine factors aromatase and, 93, 116  
 lung cancer molecular pathogenesis and, 682-84  
 Paralogs aromatase and, 98  
*Paramecium* spp. calmodulin as ion-channel subunit and, 289, 291-93, 299, 302-4  
 hypoxia-induced anapryxia and, 266-67, 271  
 PDZ domains renal organic anionic transporters and, 578-81  
 Peptide transporter (PEPT) protein renal organic anionic

- transporters and, 563, 578
- Peripheral chemoreceptors  
hypoxia-induced  
anapnoea and, 263
- Peripheral neuropathy  
cation-Cl cotransporter  
phenotypes and, 803,  
828–29
- Peristaltic machinery  
urinary  
renin angiotensin system  
and kidney  
development, 555–57
- Peutz-Jegher syndrome  
aromatase and, 108
- pH sensitivity  
active  $\text{Ca}^{2+}$  absorption in  
distal nephron and, 541
- Phenotypic analysis  
cation-Cl cotransporter  
phenotypes and, 803–43  
ENaC and sodium balance,  
878–80, 886–87, 889  
lung cancer molecular  
pathogenesis and, 695  
renin angiotensin system  
and kidney development,  
553–55
- Phenylalkylamines  
cardiac ion channels and,  
445
- Pheromone signaling  
G proteins and, 129–43
- Phorbol myristate acetate  
(PMA)  
intracellular signal  
transport and, 409–10,  
412–13, 415–16  
ovulation regulators and,  
78
- Phosducin  
G proteins and  
phototransduction,  
171–72
- Phosphate groups  
sodium pumping and, 1,  
6–14
- Phosphodiesterases  
G proteins and olfactory  
signal transduction,  
199–200  
G proteins and  
phototransduction,  
153–80
- Phosphorylation  
endothelial nitric oxide  
synthase regulation and,  
749, 762–63  
prolactin and, 53
- Photoisomerization  
G proteins and  
phototransduction, 156
- Photooxidative stress  
MAAs in aquatic  
organisms and, 223
- Photosynthetically-available  
radiation (PAR)  
MAAs in aquatic  
organisms and, 223–52
- Phototransduction  
G proteins and, 153–80
- PI3-kinase  
trafficking of canalicular  
ABC transporters in  
hepatocytes and, 595–605
- Pituitary gland  
prolactin and, 47, 52–53
- Placenta  
aromatase and, 96–98,  
105–6
- Plasma  
renal genetic disorders  
related to  $\text{K}^+$  and  $\text{Mg}^{2+}$ ,  
845–66
- Plasma membrane  
endothelial nitric oxide  
synthase regulation and,  
749, 753–68  
fatty acid  $\beta$ -oxidation  
disorders and, 477–96  
hepatocyte chloride  
channels and, 609–16  
 $\text{K}^+$  channel ontogeny and,  
19–37
- Plasmodium falciparum*  
MAAs in aquatic  
organisms and, 246
- Plasticity  
dendritic spines and,  
323–42  
short-term synaptic  
plasticity and, 355–88
- PLP1/2 proteins  
G proteins and pheromone  
signaling, 137–40
- Pneumocystis carinii*  
GM-CSF regulation of  
lung functions and, 790
- Pocillopora damicornis*  
MAAs in aquatic  
organisms and, 225, 228,  
247
- Polyamine block  
short-term synaptic  
plasticity and, 379
- Polygenic diseases  
ENaC and sodium balance,  
889–90
- Polytopic membrane proteins  
 $\text{K}^+$  channel ontogeny and,  
19–37
- Pore-forming hydrophobic  
stretch  
active  $\text{Ca}^{2+}$  absorption in  
distal nephron and, 529
- Pore-forming units  
 $\text{K}^+$  channel ontogeny and,  
19, 27–28
- Porites* spp.  
MAAs in aquatic  
organisms and, 225, 247
- Porphyra tenera*  
MAAs in aquatic  
organisms and, 226
- Postmenopause  
aromatase and, 94, 119
- Postmortem screening  
fatty acid  $\beta$ -oxidation  
disorders and, 494–95
- Postsynaptic mechanisms  
short-term synaptic

- plasticity and, 378–79
- Post-tetanic potentiation
- short-term synaptic plasticity and, 355–57
- Posttranscriptional regulation
- bile-salt transporters and, 635, 641–42
- Posttranslational modification
- endothelial nitric oxide synthase regulation and, 749
- G proteins and pheromone signaling, 135
- Potentiation
- short-term synaptic plasticity and, 360–61, 366
- PPAR $\gamma$  factor
- aromatase and, 102–3, 105, 117–18
- Prenatal diagnosis
- fatty acid  $\beta$ -oxidation disorders and, 491
- Preneoplasia
- lung cancer molecular pathogenesis and, 681
- Presynaptic changes
- short-term synaptic plasticity and, 357–61, 376
- Prochloron* spp.
- MAAs in aquatic organisms and, 228
- Progesterone
- ovulation regulators and, 69, 78–79, 81–82
- renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 845–66
- Prognostic markers
- lung cancer molecular pathogenesis and, 697
- Prolactin (PRL)
- animal models, 54–58
- conclusions, 59–60
- cytokines, 48
- extrapituitary PRL, 52–53
- functions, 51–58
- human pathophysiology, 58–59
- isoforms, 53, 54
- mechanisms, 51–58
- nucleus, 51–52
- phenotypes
- behavior, 56–57
- bone, 57
- controversial, 58
- expected, 54–57
- Harderian gland development, 57
- immunity, 58
- lacrimal gland development, 57
- male fertility, 57
- mammary gland development, 55–56
- metabolic status, 57–58
- reproductive, 54–55
- unexpected, 57–58
- 16K PRL, 53–54
- pseudophosphorylated PRL, 53
- receptor, 49–51
- regulation, 47–48
- structure, 47–48
- Promoters
- lung cancer molecular pathogenesis and, 691
- Propafenone
- cardiac ion channels and, 447
- Prostaglandins
- aromatase and, 104, 108
- cation-Cl cotransporter phenotypes and, 816–17
- Prostate cancer
- prolactin and, 47
- Proteases
- ovulation regulators and, 69–70, 74, 76, 78–79, 81
- Protein folding
- K<sup>+</sup> channel ontogeny and, 19, 27
- Protein kinase A (PKA)
- aromatase and, 100
- cardiac ion channels and, 442, 446, 454, 456
- intracellular signal transport and, 407, 409, 414, 420–21, 423
- Protein kinase C (PKC)
- aromatase and, 102, 107
- cardiac ion channels and, 442, 454, 456
- intracellular signal transport and, 407–20, 423
- Proteoglycans
- ovulation regulators and, 79–80, 82
- Protozoa
- hypoxia-induced anapryxia and, 263–79
- Proximal renal tubular acidosis
- genetic diseases of acid-base transporters and, 913–14
- Pseudoaldosteronism
- ENaC and sodium balance, 877–78
- renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 848–50, 862
- Pseudoalteromonas* spp.
- MAAs in aquatic organisms and, 227
- Pseudofacilitation
- short-term synaptic plasticity and, 362
- Pseudohypoaldosteronism
- cation-Cl cotransporter phenotypes and, 817–18
- ENaC and sodium balance, 877–78, 880, 884–87
- renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 850, 857–59, 862
- Pseudomonas* spp.
- renal genetic disorders

- related to  $K^+$  and  $Mg^{2+}$ , 858
- Pseudophosphorylation prolactin and, 53
- Pseudopleuronectes americanus* cation-Cl cotransporter phenotypes and, 818
- PU.1 transcription factor GM-CSF regulation of lung functions and, 791-93
- Pulmonary alveolar proteinosis GM-CSF regulation of lung functions and, 775, 782-90, 793
- Purkinje cells dendritic spines and, 337-38
- Pyramidal cells dendritic spines and, 335-37
- Q**
- Quinidine cardiac ion channels and, 447, 456
- R**
- R\* G proteins and phototransduction, 156-62, 164-67, 169, 171-73, 177
- Rab GTPases intracellular signal transport and, 407, 409, 421-23
- RAS oncogenes lung cancer molecular pathogenesis and, 684-85
- Reabsorption active  $Ca^{2+}$  absorption in distal nephron and, 542-44 genetic diseases of acid-base transporters and, 915-16
- Receptors for activated C-kinase (RACKs) intracellular signal transport and, 410-11, 413-14, 416, 418, 423
- Recognition domains  $K^+$  channel ontogeny and, 24-25
- Renal genetic disorders related to  $K^+$  and  $Mg^{2+}$  apparent mineralocorticoid excess syndrome, 851-52 Bartter's syndrome, 853-54, 864-65 conclusions, 865-66 familial hyperkalemia with hypertension, 859-62 familial hypoaldosteronism, type I, 850-51 familial hypoaldosteronism, type II, 851 familial hypomagnesemia with hypercalciuria and nephrocalcinosis, 863 familial hypomagnesemia with hypocalciuria, 864 Gitelman's syndrome, 854-57, 864-65 glucocorticoid-remediable aldosteronism, 850-51 hypomagnesemia with secondary hypocalcemia, 864 introduction, 845 Liddle's syndrome, 848-49 magnesium disorders, 862-65 magnesium wasting, 864-65 pseudoaldosteronism, 862 pseudohypoaldosteronism, type I, 857-59, 862 renal  $K^+$  handling, 845-48 renal  $K^+$  retention syndromes, 857-62 renal  $K^+$  wasting disorders with high plasma renin activity, 852-57 renal  $K^+$  wasting disorders with low plasma renin activity, 848-52 S810L in mineralocorticoid receptor, 849, 850 suggested nomenclature, 862
- Renal transplantation renal molecular chaperones and, 516
- Renin cation-Cl cotransporter phenotypes and, 810, 814-15 ENaC and sodium balance, 887, 889-90 renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 845, 848-57
- Renin angiotensin system kidney development and abnormal kidney phenotypes of AngII- and AT1-deficient mutants, 553-55 adult urinary tract, 557-58 induction of urinary peristaltic machinery at birth, 555-57

- introduction, 551-52  
maturation of kidney and  
urinary tract during  
perinatal period, 552  
perinatal Ang 11/AT1  
expression, 552-53
- Repolarization  
cardiac ion channels  
and, 431-61
- Reproduction  
aromatase and, 93-119  
MAAs in aquatic  
organisms and, 223,  
241-42  
ovulation regulators and,  
69-84  
prolactin and, 47-60,  
54-55
- Residual  $\text{Ca}^{2+}$  hypothesis  
short-term synaptic  
plasticity and, 360-62
- Resistance-associated  
proteins  
bile-salt transporters and,  
635, 640, 644, 646-47,  
650
- Respiration  
primary disorders of  
fatty acid  $\beta$ -oxidation  
disorders and, 490-91
- Response timing  
G proteins and  
phototransduction,  
153-80
- REST silencing element  
cardiac ion channels and,  
442
- Retention  
 $\text{K}^+$  channel ontogeny and,  
19, 31
- Reticuloendothelial  
macrophages  
iron accumulation in  
hereditary  
hemochromatosis and,  
665
- Retinoic acid receptor (RXR)  
aromatase and, 102, 105,  
118
- Retrograde control  
short-term synaptic  
plasticity and, 376
- RGS proteins  
G proteins and pheromone  
signaling, 129-43  
G proteins and  
phototransduction,  
175-76
- Rhodopsin  
G proteins and  
phototransduction, 153,  
161, 163-64
- RICKs  
intracellular signal  
transport and, 410
- Rods  
vertebrate  
G proteins and  
phototransduction,  
153-80
- Rosiglitazone  
aromatase and, 102, 117
- Rubidium  
sodium pumping and, 11
- rutabaga* mutant  
short-term synaptic  
plasticity and, 384
- Ryanodine receptor (RyR)  
calmodulin as ion-channel  
subunit and, 295, 296  
cardiac ion channels and,  
446
- S**
- S801L mutation  
renal genetic disorders  
related to  $\text{K}^+$  and  $\text{Mg}^{2+}$ ,  
849-50
- Saccharomyces cerevisiae*  
calmodulin as ion-channel  
subunit and, 292  
G proteins and pheromone  
signaling, 129-43  
genetic diseases of  
acid-base transporters  
and, 909-10  
intracellular signal  
transport and, 421
- Salivary gland phenotype  
cation-Cl cotransporter  
phenotypes and, 803, 809
- Salt intake/wasting  
ENaC and sodium balance,  
877, 879-80, 884, 886,  
888
- Schizophrenia  
dendritic spines and, 329
- Schizosaccharomyces pombe*  
calmodulin as ion-channel  
subunit and, 292
- SCL15A carrier family  
renal organic anionic  
transporters and, 578
- SCNSA* gene  
cardiac ion channels and,  
441-44
- Seasonality  
MAAs in aquatic  
organisms and, 231-32
- Second messengers  
G proteins and olfactory  
signal transduction,  
189-210
- Seizures  
cation-Cl cotransporter  
phenotypes and, 803,  
824-25
- Selective aromatase  
modulators (SAMs)  
aromatase and, 93, 118-19
- Sensorineural deafness  
cation-Cl cotransporter  
phenotypes and, 808-9
- Sensory perception  
phenotype  
cation-Cl cotransporter  
phenotypes and, 810-11
- Sepia officinalis*  
MAAs in aquatic  
organisms and, 230, 249
- SERMS



- aromatase and, 119
- Set point
- thermoregulatory
  - hypoxia-induced
  - anaprexia and, 263–65
- SF1 transcription factor
- aromatase and, 96, 99–100, 105, 108, 118
- Shaker* Kv channels
- K<sup>+</sup> channel ontogeny and, 20, 23–27, 29–30
- shaker* mutant
- cardiac ion channels and, 436, 440, 447, 456
- shaker/walzer* phenotype
- cation-Cl cotransporter phenotypes and, 808–9
- Shal* Kv channels
- K<sup>+</sup> channel ontogeny and, 29
- SHAP protein
- ovulation regulators and, 71, 73
- Shikimate pathway
- MAAs in aquatic organisms and, 236, 245–49
- Short-chain fatty acid
- $\beta$ -oxidation disorders
  - fatty acid  $\beta$ -oxidation disorders and, 489
- Short-term synaptic plasticity
- augmentation, 360–61, 366
  - buffering presynaptic [Ca<sup>2+</sup>]<sub>i</sub> reduces
  - short-term enhancement, 361
- Ca<sup>2+</sup>
- Ca<sup>2+</sup> ions, 359–67
  - Ca<sup>2+</sup>-binding proteins, 381–85
  - Ca<sup>2+</sup>-dependent
  - recovery from depression, 373–74
  - use-dependent changes in Ca<sup>2+</sup> entry, 367–68
  - conclusions, 388
- depletion models of depression, 369–75
- depression inconsistent with depletion models, 374–75
- desensitization, 378–79
- difficulty in identifying specific effects on short-term plasticity, 380–82
- Drosophila* mutants, 384–85
- elevating presynaptic Ca<sup>2+</sup>
- enhances AP-evoked release, 361
- enhancement of transmission, 356–59
- facilitation, 356–57, 360–61, 366–67
- glia, 377–78
- heterosynaptic inhibition, 376
- homosynaptic inhibition, 375–76
- introduction, 355–56
- kinetics, 366–67
- miscellaneous modulatory influences, 385–88
- mobilization, 367
- molecular targets in synaptic enhancement, 379–88
- mouse mutants, 383–84
- multiple site hypotheses, 364–67
- multivesicular release, 373
- perspectives, 388
- postsynaptic mechanisms of synaptic depression, 378–79
- post-tetanic potentiation, 356–57
- potentiation, 360–66
- presynaptic [Ca<sup>2+</sup>]<sub>i</sub>, 360–61
- presynaptic changes, 357–59
- presynaptic ionotropic receptors, 376–77
- pseudofacilitation, 362
- readily releasable pool at release sites, 371–72
- reducing Ca<sup>2+</sup> influx
- reduces short-term enhancement, 361–62
  - release statistics, 357–59
  - relief of polyamine block, 379
- residual Ca<sup>2+</sup> hypothesis, 360–62
- retrograde control of neurotransmitter release, 376
- secretory proteins, 381–83
- single-site hypothesis, 362–64
- single-vesicle release, 373
- sites of Ca<sup>2+</sup> action, 365–66
- slow release, 367
- summary of molecular mediators, 385
- synapses that show no depression, 374
- synapsin hypothesis, 381
- synaptic depression via activation of metabotropic receptors, 375–76
- synaptic enhancement, 367
- time course of enhancement, 364–65
- Signal transduction
- dendritic spines and, 313, 333
  - endothelial nitric oxide synthase regulation and, 749–68
  - GM-CSF regulation of lung functions and, 775–93
  - G proteins and pheromone signaling, 129–43
  - G proteins and phototransduction, 153–80



- intracellular signal transport and, 407  
 olfactory, 189–210  
 ovulation regulators and, 70, 81  
 prolactin receptor and, 50–51
- Single-nucleotide polymorphisms (SNPs)  
 ENaC and sodium balance, 879, 889
- Single-site hypothesis  
 short-term synaptic plasticity and, 362–64
- Sinularia flexibilis*  
 MAAs in aquatic organisms and, 232, 240
- SK channels  
 calmodulin as ion-channel subunit and, 296–97  
 K<sup>+</sup> channel ontogeny and, 28
- SKT1 channel  
 K<sup>+</sup> channel ontogeny and, 25
- SLC22A solute carrier family  
 renal organic anionic transporters and, 576–78
- SLC26A Cl<sup>-</sup>/base exchangers  
 genetic diseases of  
 acid-base transporters and, 906–11
- Slow delayed rectifier K<sup>+</sup> currents  
 cardiac ion channels and, 453–55
- Small intestine  
 bile-salt transporters and, 635–37, 648
- Smoke-damaged respiratory epithelium  
 lung cancer molecular pathogenesis and, 693–94
- SNARE proteins  
 intracellular signal transport and, 421
- short-term synaptic plasticity and, 383
- Sodium balance  
 ENaC and, 877–90
- Sodium bicarbonate cotransporter  
 genetic diseases of  
 acid-base transporters and, 899–916
- Sodium nitroprusside  
 hypoxia-induced anapnoea and, 274, 277
- Sodium/phosphate cotransporter type 1 (NPT1)  
 renal organic anionic transporters and, 563–74
- Sodium pumping  
 history of research, 1–14
- Solute carrier family 22A  
 renal organic anionic transporters and, 572–73
- SOX-9* gene  
 ovulation regulators and, 82
- SP-D protein  
 GM-CSF regulation of lung functions and, 786
- Spatial factors  
 ovulation regulators and, 69, 76
- SPC-GM<sup>+/+</sup>/CM<sup>-/-</sup> mice  
 GM-CSF regulation of lung functions and, 785
- Spermatogenesis  
 cation-Cl cotransporter phenotypes and, 803
- “Spike and dome”  
 configuration  
 cardiac ion channels and, 444
- Spironolactone  
 renal genetic disorders related to K<sup>+</sup> and Mg<sup>2+</sup>, 850, 857
- SR-BI receptor  
 endothelial nitric oxide synthase regulation and, 749, 765–66, 768
- SST2 protein  
 G proteins and pheromone signaling, 129, 137–42
- STE proteins  
 G proteins and pheromone signaling, 132–35
- Sterechnus neumayeri*  
 MAAs in aquatic organisms and, 231–32
- Stereum hirsutum*  
 MAAs in aquatic organisms and, 226
- Steroids  
 aromatase and, 93, 99, 116–17
- Stoichiometry  
 G proteins and phototransduction, 167–68  
 K<sup>+</sup> channel ontogeny and, 19, 29–30, 34–35
- Streptococcus* spp.  
 Group B  
 GM-CSF regulation of lung functions and, 790
- Stress proteins  
 renal molecular chaperones and, 503–18
- Strongylocentrotus droebachiensis*  
 MAAs in aquatic organisms and, 231, 238, 241
- Structural plasticity  
 dendritic spines and, 320–28, 330
- Stylophora pistillata*  
 MAAs in aquatic organisms and, 245, 248
- Subcellular transport  
 intracellular signal transport and, 409–14
- Substrate specificity  
 intracellular signal transport and, 409–14

- Sulfonylurea receptor  
cardiac ion channels and, 457–58
- Sunscreens  
MAAs in aquatic organisms and, 223, 227, 229, 233–35, 241
- Surfactant homeostasis  
GM-CSF regulation of lung functions and, 775–93
- Swelling-activated chloride channels  
hepatocyte chloride channels and, 609–15
- SYG1 protein  
G proteins and pheromone signaling, 137–40
- Symbiodinium* sp.  
MAAs in aquatic organisms and, 228–29
- Symbiosis  
MAAs in aquatic organisms and, 223, 228–29
- Synapses  
short-term synaptic plasticity and, 381
- Synaptic activity-dependent structural plasticity  
dendritic spines and, 323–24
- Synaptic plasticity  
dendritic spines and, 323–42  
short-term synaptic plasticity and, 355–88
- Syndecans  
ovulation regulators and, 79
- Synergy  
 $\beta$ -defensins in lung host defense and, 732–33
- T**
- T1 domain  
 $K^+$  channel ontogeny and, 24–25, 36
- Targeted deletion  
ovulation regulators and, 69
- Targeting  
cation-Cl cotransporter phenotypes and, 803  
 $K^+$  channel ontogeny and, 20, 32, 33
- Targeting prediction  
renal organic anionic transporters and, 579
- T cells  
 $\beta$ -defensins in lung host defense and, 709
- Telomerase  
lung cancer molecular pathogenesis and, 695
- Temporal factors  
ovulation regulators and, 69, 76
- Testosterone  
aromatase and, 110, 113, 117
- Tetraethylammonium  
cardiac ion channels and, 456
- Tetramerization  
 $K^+$  channel ontogeny and, 24–27, 30, 36
- Tetraprotomers  
sodium pumping and, 13
- Tetrodotoxin  
cardiac ion channels and, 441
- Theca cells  
ovulation regulators and, 70, 75–77, 79
- Thelonata ananas*  
MAAs in aquatic organisms and, 250, 251
- Thermodynamics  
sodium pumping and, 1
- Thiazide diuretics  
active  $Ca^{2+}$  absorption in distal nephron and, 529, 540–41  
cation-Cl cotransporter phenotypes and, 818–20  
renal genetic disorders related to  $K^+$  and  $Mg^{2+}$ , 854–55, 857
- Thrombospondins  
ovulation regulators and, 80–81
- TIMP* genes  
ovulation regulators and, 75–76
- Tissue specificity  
aromatase and, 93, 99–108  
fatty acid  $\beta$ -oxidation disorders and, 477
- TNF-activating protein  
ovulation regulators and, 76
- Tobacco smoke carcinogens  
lung cancer molecular pathogenesis and, 693–97
- Topogenic duality  
 $K^+$  channel ontogeny and, 35
- Torpedo marmorata*  
hepatocyte chloride channels and, 620
- Torsades de Pointes  
cardiac ion channels and, 450–54, 457
- Trafficking  
canalicular ABC transporters in hepatocytes and, 595–605  
endothelial nitric oxide synthase regulation and, 749, 753–57, 767  
intracellular signal transport and, 421–23  
 $K^+$  channel ontogeny and, 19, 31–34
- Transcription factors  
aromatase and, 93, 96, 99–100, 102
- Transcriptional regulation  
bile-salt transporters and, 635, 641–42, 649  
GM-CSF regulation of

- lung functions and, 791
- Transducin  
G proteins and  
phototransduction,  
153-80
- Transferrin receptor  
iron accumulation in  
hereditary  
hemochromatosis and,  
663, 665, 669-72
- Transgenes  
bile-salt transporters and,  
641  
ENaC and sodium balance,  
883, 887  
GM-CSF regulation of lung  
functions and, 775-93  
G proteins and  
phototransduction, 175,  
178  
intracellular signal  
transport and, 417-19
- Transient outward current  
cardiac ion channels and,  
447-48
- Transient receptor potential  
channels  
active  $\text{Ca}^{2+}$  absorption in  
distal nephron and, 529
- Translocases  
fatty acid  $\beta$ -oxidation  
disorders and, 485
- Translocation  
intracellular signal  
transport and, 22-38  
 $\text{K}^+$  channel ontogeny and,  
19-23, 27, 29
- Transmembrane segments  
 $\text{K}^+$  channel ontogeny and,  
19, 22-23
- Transmembrane-spanning  
domains  
active  $\text{Ca}^{2+}$  absorption in  
distal nephron and, 529
- Transplantation  
kidney  
renal molecular  
chaperones and, 516
- Transport proteins  
active  $\text{Ca}^{2+}$  absorption in  
distal nephron and, 529  
bile-salt transporters and,  
635  
cation-Cl cotransporter  
phenotypes and, 803-43  
genetic diseases of  
acid-base transporters  
and, 899-916  
intracellular signal  
transport and, 409-14  
renal genetic disorders  
related to  $\text{K}^+$  and  $\text{Mg}^{2+}$ ,  
845-66  
renal organic anionic  
transporters and, 563-84
- Trifunctional protein  
deficiency  
fatty acid  $\beta$ -oxidation  
disorders and, 486-87
- Triglycerides  
aromatase and, 109
- Troglitazone  
aromatase and, 102, 117
- Trp family channels  
calmodulin as ion-channel  
subunit and, 289, 297-98
- Trypsin  
sodium pumping and, 11
- TSG-6 gene  
ovulation regulators and,  
69, 71-73, 77
- Tumor necrosis factor  $\alpha$   
(TNF- $\alpha$ )  
aromatase and, 96, 100-4,  
106, 117
- Tumor suppressor genes  
lung cancer molecular  
pathogenesis and, 681,  
686-93
- U  
U-50,488H  
hypoxia-induced  
anapylaxia and, 271
- Ultrarapid delayed rectifier  
 $\text{K}^+$  currents  
cardiac ion channels and,  
456-57
- Ultraviolet radiation (UVR)  
MAAs in aquatic  
organisms and, 223-52
- Urinary acidification  
genetic diseases of  
acid-base transporters  
and, 900-6
- V  
Vacuolar  $\text{H}^+$ -ATPase  
genetic diseases of  
acid-base transporters  
and, 899, 907-11
- Vanilloid receptor  
active  $\text{Ca}^{2+}$  absorption in  
distal nephron and, 529
- Vascular epithelium  
aromatase and, 93  
endothelial nitric oxide  
synthase regulation and,  
749, 750-51
- Vascular hypertrophy  
renin angiotensin system  
and kidney development,  
551
- Vasopressin  
cation-Cl cotransporter  
phenotypes and, 814, 817  
ENaC and sodium balance,  
880
- Verapamil  
cardiac ion channels and,  
445
- Vertebrate rod  
phototransduction  
G proteins and  
phototransduction,  
153-80
- Vertebrates  
 $\beta$ -defensins in lung host  
defense and, 719, 720-23  
MAAs in aquatic  
organisms and, 229-30

- Very-long-chain acyl-CoA dehydrogenase deficiency  
fatty acid  $\beta$ -oxidation disorders and, 485–86
- Vibrio* spp.  
MAAs in aquatic organisms and, 227, 251
- Viruses  
 $\beta$ -defensins in lung host defense and, 709  
lung cancer molecular pathogenesis and, 695–96
- Vision  
MAAs in aquatic organisms and, 243–44
- Visual pigment  
G proteins and phototransduction, 153–80
- Vitamin D  
active  $\text{Ca}^{2+}$  absorption in distal nephron and, 529–30
- Voltage gating  
calmodulin as ion-channel subunit and, 289, 293–94  
cardiac ion channels and, 438–39  
dendritic spines and, 313, 334–41  
hepatocyte chloride channels and, 609, 621, 625–26
- W**
- Wasting disorders  
renal genetic disorders related to  $\text{K}^+$  and  $\text{Mg}^{2+}$ , 848–57
- Water  
MAAs in aquatic organisms and, 223–52
- weaver* mutant  
dendritic spines and, 322
- Wingless* gene  
ovulation regulators and, 71
- Wnt4* gene  
ovulation regulators and, 71
- Wnts* gene  
ovulation regulators and, 82–84
- X**
- Xenopus laevis*  
bile-salt transporters and, 640  
cardiac ion channels and, 440, 453  
cation-Cl cotransporter phenotypes and, 811, 813, 818, 820  
ENaC and sodium balance, 881, 887–88  
G proteins and olfactory signal transduction, 204
- G proteins and phototransduction, 175, 178  
genetic diseases of acid-base transporters and, 903–4, 906  
intracellular signal transport and, 411  
 $\text{K}^+$  channel ontogeny and, 30, 33  
renal organic anionic transporters and, 573
- X-linked osteopetrosis  
genetic diseases of acid-base transporters and, 899
- Y**
- Yeast  
genetic diseases of acid-base transporters and, 909–10  
G proteins and pheromone signaling, 129–43  
intracellular signal transport and, 421
- Z**
- ZIP proteins  
cardiac ion channels and, 457
- ZnDPBG  
hypoxia-induced anapryrexia and, 275–76

